Schering-Plough Corporation

Nov 20, 09
	NEW STORY
08:07 ET	Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R)
Nov 02, 09
17:30 ET	Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
10:26 ET	Schering-Plough Announces Sponsorship of Rabies-Control Projects in India
08:38 ET	Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
Nov 01, 09
17:00 ET	Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
Oct 30, 09
14:12 ET	U.S. Food and Drug Administration Issues Complete Response Letter Regarding PEGINTRON(R) for Malignant Melanoma
Oct 22, 09
06:30 ET	Schering-Plough Reports Financial Results for 2009 Third Quarter
Oct 15, 09
08:30 ET	Schering-Plough Highlights Boceprevir, Narlaprevir (SCH 900518) and PEGINTRON(R) Data at the American Association for the Study of Liver Diseases (AASLD) 2009 Annual Meeting
Oct 13, 09
08:00 ET	Nobilon Advances Intranasal Seasonal Influenza Vaccine Into Proof of Concept Study
Oct 12, 09
17:24 ET	Schering-Plough Schedules Conference Call Webcast For 2009 Third Quarter Earnings
Oct 08, 09
08:37 ET	Intervet/Schering-Plough Animal Health Announces Sponsorship Supporting Milk Producers In Malawi
Oct 06, 09
11:14 ET	SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Oct 05, 09
13:26 ET	FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Sep 18, 09
11:43 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Sep 14, 09
08:00 ET	Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
07:00 ET	Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Sep 03, 09
08:00 ET	Dieter Lutticken Award 2008 for Alternatives in Animal Testing Presented to Dr. Ivo Claassen (The Netherlands)
Sep 01, 09
07:47 ET	New Non-Drowsy CLARITIN(R) 12-Hour Gets Allergy Sufferers Through Their Busy Day
Aug 26, 09
11:16 ET	Schering-Plough Announces Two European Filings
Aug 11, 09
18:08 ET	Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
07:47 ET	Photos: New CLARITIN(R) Eye Relieves Itchy Eyes For Up To 12 Hours
Aug 07, 09
13:49 ET	Schering-Plough Shareholders Approve Merger With Merck
Aug 06, 09
16:48 ET	Schering-Plough to Webcast Special Meeting of Shareholders
Jul 30, 09
15:32 ET	FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
Jul 24, 09
10:07 ET	SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
08:30 ET	Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck
Jul 22, 09
16:35 ET	Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
Jul 21, 09
06:45 ET	Schering-Plough Reports Financial Results for 2009 Second Quarter
Jul 15, 09
08:30 ET	Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
Jul 09, 09
16:07 ET	REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients
16:06 ET	ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
Jul 01, 09
09:00 ET	Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
Jun 29, 09
11:14 ET	Schering-Plough Schedules Conference Call Webcast for 2009 Second Quarter Earnings
Jun 26, 09
05:00 ET	SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Jun 23, 09
14:00 ET	New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus
09:57 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Jun 17, 09
07:47 ET	The New York Yankees' Mark Teixeira, National Foundation For Cancer Research, and the Makers of COPPERTONE SPORT(R) Launch 'Help Strike Out Sun Damage' Program
Jun 10, 09
01:00 ET	New Survey Reveals That More Than Half of Rheumatoid Arthritis Patients in Europe and Canada Feel Their Disease Controls Their Lives
Jun 02, 09
03:00 ET	Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
May 19, 09
07:37 ET	Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males
01:00 ET	Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
May 18, 09
10:27 ET	Photos: Schering-Plough Introduces DR. SCHOLL'S(R) FOR HER High Heel Insoles to Help Prevent Foot Aches and Pains
May 14, 09
07:49 ET	Introducing COPPERTONE(R) NutraShield(R) With Dual Defense(R), New Sunscreen Line With Antioxidants To Help Promote Natural Skin Repair
May 11, 09
08:25 ET	Schering-Plough Schedules Webcast For Annual Meeting of Shareholders
08:00 ET	Schering-Plough Starts Patient Enrollment in Phase 3 Trial for Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
Apr 29, 09
16:30 ET	Schering-Plough Flips the Switch on 1.7 MW Rooftop Solar Panel System, One of the Largest in N.J., North America
Apr 27, 09
02:00 ET	Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
Apr 23, 09
10:30 ET	Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Apr 22, 09
07:47 ET	Video: NASONEX(R) (Mometasone Furoate Monohydrate) Nasal Spray, 50 mcg* Teams Up With American Forests to Educate Nasal Allergy Sufferers and Help Improve Air Quality
Apr 21, 09
06:18 ET	Schering-Plough Reports Financial Results for 2009 First Quarter
Apr 13, 09
16:15 ET	Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Apr 07, 09
06:00 ET	Dieter Luetticken Award 2008 Recognizes Development of New Vaccine Quality Control Assay
Mar 30, 09
11:20 ET	Schering-Plough Announces Results of the Early ACS Trial
09:30 ET	EPA Names Schering-Plough 2009 EPA ENERGY STAR(R) Partner of the Year
Mar 24, 09
07:37 ET	Video: New Children's Storybook Helps Parents Teach Their Children With Asthma About Their Condition
Mar 18, 09
08:00 ET	Video: CLARITIN Partners with NASCAR Driver Carl Edwards to Educate Motorists on the Importance of Being Clear to Drive(SM)
Mar 13, 09
14:09 ET	Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
Mar 12, 09
18:30 ET	Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
16:39 ET	Schering-Plough Schedules Conference Call Webcast for 2009 First Quarter Earnings
Mar 11, 09
14:45 ET	FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Mar 09, 09
13:39 ET	Schering-Plough Withdraws From Barclays Capital Global Healthcare Conference
Mar 05, 09
16:30 ET	Schering-Plough to Webcast Presentation at Barclays Capital Global Healthcare Conference
08:00 ET	European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors
Mar 03, 09
08:45 ET	Video: Schering-Plough Introduces AFRIN(R) PureSea(TM): A Natural, Gentle Nasal Rinse From the Seas of Northern France
Feb 27, 09
13:10 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Feb 23, 09
08:00 ET	Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
Feb 20, 09
07:30 ET	Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Feb 12, 09
07:30 ET	Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards
Feb 03, 09
06:45 ET	Schering-Plough Reports Financial Results for 2008 Fourth Quarter, Full Year
Jan 27, 09
10:00 ET	Brooke Shields and the Makers of COPPERTONE(R) Join Together to Launch COPPERTONE(R) NutraShield(TM) - New Sunscreen Contains Antioxidants That Promote Natural Skin Repair
07:30 ET	Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Jan 14, 09
10:00 ET	New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
06:30 ET	U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Jan 09, 09
09:28 ET	Schering-Plough to Webcast Presentation at 27th Annual J.P. Morgan Healthcare Conference
Jan 06, 09
12:26 ET	Schering-Plough Schedules Conference Call and Webcast for 2008 Fourth Quarter and Full Year Earnings
Dec 31, 08
09:51 ET	Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
Dec 19, 08
13:10 ET	Schering-Plough Provides Update on Dividend Payment Date for Mandatory Convertible Preferred Stock
Dec 12, 08
10:51 ET	Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
Dec 10, 08
10:03 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Dec 08, 08
08:00 ET	CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
Nov 24, 08
13:01 ET	Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
11:21 ET	Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
10:35 ET	Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease
10:35 ET	Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
Nov 07, 08
11:58 ET	Schering-Plough to Webcast R&D Update Meeting
Nov 01, 08
11:00 ET	Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Oct 30, 08
17:29 ET	Schering-Plough to Appeal Jury Decision in Missouri Reimbursement Case
Oct 28, 08
08:30 ET	Sugammadex Study First to Show Rapid Reversal of Profound Rocuronium-Induced Muscle Relaxation is Possible
Oct 26, 08
11:15 ET	Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
Oct 23, 08
13:23 ET	Asenapine Meets Primary Endpoint in Long-Term Schizophrenia Relapse Prevention Trial
Oct 21, 08
06:47 ET	Schering-Plough Reports Financial Results for Third Quarter of 2008
Oct 17, 08
11:47 ET	Schering-Plough Announces Transition of Animal Health Leadership
Oct 16, 08
14:05 ET	Women's Contraceptive Perceptions and Realities Don't Match Up
Sep 23, 08
16:30 ET	Schering-Plough Schedules Conference Call and Webcast for 2008 Third Quarter Earnings
Sep 16, 08
11:42 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Sep 10, 08
17:31 ET	Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products to Pfizer
14:57 ET	Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
Aug 12, 08
08:30 ET	Schering-Plough Expands Its Presence in China, Enters Next Stage of Development
Aug 05, 08
07:30 ET	World Champion Gymnast Shannon Miller Forms Winning Partnership with Non-Drowsy Claritin(R)
Aug 04, 08
08:00 ET	Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
Aug 01, 08
07:00 ET	U.S. FDA Issues Action Letter for Sugammadex
Jul 29, 08
16:45 ET	BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
Jul 21, 08
16:05 ET	Schering-Plough Reports Financial Results for Second Quarter of 2008
06:45 ET	Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
Jul 17, 08
10:40 ET	NASONEX(R) Now Approved in Japan for the Treatment of Allergic Rhinitis in Adult Patients
Jul 11, 08
10:19 ET	Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Jul 08, 08
09:50 ET	Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Jul 02, 08
02:00 ET	Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
Jun 27, 08
08:00 ET	Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
Jun 26, 08
07:30 ET	Survey Shows Knee and Lower Back Pain Contribute to Insomnia, Weight Gain, Money Loss and More
Jun 24, 08
13:23 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Jun 17, 08
10:37 ET	Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
Jun 11, 08
16:00 ET	Schering-Plough Announces Fruit of the Earth to Change Sun Care Packaging After Court Hearing
Jun 03, 08
08:30 ET	ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
Jun 02, 08
08:19 ET	Schering-Plough's Sugammadex Provides Fast Reversal of Effects of Muscle Relaxants Used in General Anesthesia
06:51 ET	European Union's CHMP Issues Positive Opinion on Sugammadex
May 30, 08
15:31 ET	About 60 Clinical Studies Regarding Schering-Plough's Oncology Compounds Will be Presented at ASCO
May 27, 08
12:06 ET	Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
May 21, 08
12:31 ET	Schering-Plough Elects Tessa Hilado Vice President and Treasurer
11:54 ET	Hurricane Season Begins June 1 - Pets Need Protection, Too!
08:30 ET	Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
May 19, 08
13:46 ET	Prof. Dr. George Gettinby Honored With Dieter Lutticken Award
May 15, 08
16:25 ET	Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
May 09, 08
13:37 ET	Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
May 08, 08
11:00 ET	Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
May 06, 08
08:30 ET	Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
Apr 30, 08
14:29 ET	Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
Apr 26, 08
12:01 ET	Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
12:00 ET	Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
Apr 25, 08
20:59 ET	Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
Apr 24, 08
12:21 ET	Schering-Plough CEO Buys $2 Million in Common Shares
Apr 23, 08
16:30 ET	Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
06:45 ET	Schering-Plough Reports Financial Results for First Quarter of 2008
Apr 17, 08
08:30 ET	Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Apr 16, 08
13:48 ET	Schering-Plough Announces Imperfect Contraceptive Use Impacts Women's Emotional Well-Being
Apr 15, 08
13:10 ET	Video: Julianne Hough From Dancing With the Stars(TM) Has a New Partner: DR. SCHOLL'S(R) FOR HER
08:30 ET	Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
Apr 14, 08
15:17 ET	Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
Apr 11, 08
14:44 ET	Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
Apr 02, 08
17:19 ET	Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
Mar 27, 08
08:30 ET	Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Mar 20, 08
07:00 ET	New Survey Suggests Cultural Ambivalence to Allergies Leaves Many Suffering Needlessly
Mar 18, 08
13:00 ET	The Makers of COPPERTONE Launch SPF 70+ the Highest SPF Continuous Spray Sunscreen Available
08:00 ET	Video: 'Clear to Drive' Campaign Educates Motorists on How to Prevent Drowsy Driving
Mar 11, 08
17:09 ET	FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
08:00 ET	Schering-Plough Announces Filing of U.S. Application for OTC ZEGERID(R)
Mar 10, 08
17:08 ET	Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
Feb 29, 08
14:20 ET	Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
11:40 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Feb 12, 08
06:50 ET	Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Feb 11, 08
08:00 ET	Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
Feb 08, 08
15:10 ET	Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
Feb 06, 08
18:00 ET	Vicriviroc Demonstrates Potent and Sustained Viral Suppression Through 48 Weeks of Therapy in Treatment-Experienced HIV-Infected Patients
Feb 04, 08
08:00 ET	FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
Feb 01, 08
08:30 ET	Video and Photo: CLARITIN(R) Signs First-Time Sponsorship Agreement With Allergy Sufferer and NASCAR Sprint Cup Driver Carl Edwards
Jan 31, 08
14:00 ET	New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
08:00 ET	FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Jan 22, 08
08:33 ET	FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
Jan 18, 08
10:19 ET	Schering-Plough CEO to Buy $2 Million in Common Shares
Jan 17, 08
11:03 ET	Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
Jan 14, 08
09:16 ET	Schering-Plough Reports Top-Line Results of the IDEAL Study
Jan 03, 08
12:00 ET	Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
Jan 02, 08
16:55 ET	Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
Dec 27, 07
14:07 ET	Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
11:52 ET	Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
Dec 21, 07
14:40 ET	Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Dec 19, 07
14:59 ET	MiraLAX(R) #1 in Non-Fiber OTC Laxative Category
Dec 17, 07
14:22 ET	New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
Dec 14, 07
11:03 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Dec 10, 07
10:30 ET	New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
Dec 05, 07
16:58 ET	Schering-Plough Wins Three of Scrip's Top Pharma Industry Awards
Nov 26, 07
00:01 ET	Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
Nov 19, 07
10:00 ET	Schering-Plough Completes Acquisition of Organon BioSciences
Nov 16, 07
09:18 ET	Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
Nov 15, 07
02:00 ET	PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Nov 09, 07
16:20 ET	Schering-Plough to Webcast CFO Robert J. Bertolini's Presentation at 2007 Credit Suisse Health Care Conference
Nov 07, 07
10:00 ET	SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients
Nov 05, 07
16:53 ET	Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting
16:05 ET	Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
Nov 02, 07
16:23 ET	Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
Oct 30, 07
10:00 ET	Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
08:00 ET	Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
Oct 29, 07
08:37 ET	Bringing Pets Home
Oct 25, 07
08:40 ET	Schering-Plough Announces New Claritin(R) Dry Syrup Formulation Approved in Japan for Children Ages 3 to 7
Oct 22, 07
06:54 ET	Schering-Plough Reports Financial Results for Third Quarter of 2007
06:00 ET	Schering-Plough Reports Two Phase II Studies of Thrombin Receptor Antagonist (TRA) Build on Findings from Previous Phase II Study
Oct 18, 07
08:30 ET	Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Oct 11, 07
12:29 ET	Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
Sep 26, 07
17:23 ET	Schering-Plough Announces Pricing of Euro-Denominated Senior Notes Offering
Sep 24, 07
08:30 ET	European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Sep 21, 07
17:03 ET	Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
Sep 19, 07
08:53 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Sep 18, 07
15:50 ET	Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
Sep 17, 07
08:30 ET	Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Sep 13, 07
09:21 ET	Schering-Plough Announces Conversion of 2004 Mandatory Convertible Preferred Stock
Sep 12, 07
18:00 ET	Schering-Plough Announces Pricing of Senior Notes Offering
Aug 28, 07
08:00 ET	Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Aug 09, 07
20:58 ET	Schering-Plough Corporation Prices Public Offering of Common Shares and 6.00% Mandatory Convertible Preferred Stock
Aug 02, 07
13:33 ET	Schering-Plough Announces Dissolution of Consent Decree
06:30 ET	Schering-Plough Corporation Announces Commencement of Public Offering of Common Shares and Mandatory Convertible Preferred Stock
Jul 24, 07
08:30 ET	Vicriviroc Demonstrates Potent Viral Suppression Through 48 Weeks of Therapy in ACTG Phase II Study in Treatment-Experienced HIV Patients
Jul 23, 07
06:51 ET	Schering-Plough Reports Financial Results for Second Quarter of 2007
Jul 19, 07
08:30 ET	Schering-Plough Announces Licensing of Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
Jul 02, 07
14:55 ET	Actress Vanessa Williams and HomeAgain(R) Encourage Pet Owners to Take Important Summer Safety Precautions for Pets
Jun 26, 07
12:49 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Jun 25, 07
02:00 ET	PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Jun 21, 07
16:04 ET	Schering-Plough Reports on Favorable Rulings in AWP Case By U.S. District Court for District of Massachusetts
Jun 18, 07
17:28 ET	Schering-Plough Schedules Conference Call and Webcast For 2007 Second Quarter Earnings
Jun 15, 07
08:00 ET	REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Jun 12, 07
09:48 ET	Schering-Plough To Webcast CFO Robert J. Bertolini's Presentation at Goldman Sachs 28th Annual Global Healthcare Conference
Jun 11, 07
07:03 ET	Kurve Technology and Schering-Plough Sign Expanded Technology Agreement
Jun 08, 07
08:00 ET	Schering-Plough and Bayer Healthcare Announce Availability of ZETIA in Japan, the First Cholesterol-Lowering Agent With a Novel Mechanism of Action Approved in Japan in 18 Years
Jun 07, 07
08:00 ET	Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Jun 03, 07
10:30 ET	CAELYX(R) Delays Time to Disease Progression as Maintenance Therapy in Patients with Metastatic Breast Cancer
Jun 02, 07
08:30 ET	Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
May 30, 07
09:57 ET	Novacea and Schering-Plough Enter into Worldwide Development and Commercialization Agreement for Asentar, a Novel Treatment for Prostate Cancer
May 18, 07
11:15 ET	Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
May 08, 07
07:57 ET	Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
May 04, 07
09:14 ET	Schering-Plough Receives Request for Additional Information From Federal Trade Commission in Connection With Planned Organon Biosciences N.V. Transaction
Apr 30, 07
02:00 ET	European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Apr 19, 07
06:25 ET	Schering-Plough Reports Financial Results for First Quarter of 2007
Apr 18, 07
18:02 ET	Schering-Plough Announces ZETIA Approved in Japan for Treatment of High Cholesterol
17:36 ET	Schering-Plough Announces Initiation of Two Phase III Clinical Trials for Novel Selective Antiplatelet Therapy (TRA-SCH 530348)
Apr 11, 07
02:00 ET	Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Apr 09, 07
08:08 ET	Schering-Plough Schedules Conference Call and Webcast for 2007 First Quarter Earnings
Apr 05, 07
08:00 ET	PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Mar 28, 07
07:54 ET	MiraLAX(R), Number One Doctor-Prescribed Laxative, Now Available Over The Counter
Mar 26, 07
08:30 ET	Schering-Plough and Merck to Develop Another New Cholesterol Lowering Medicine
02:30 ET	European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Mar 24, 07
13:00 ET	Schering-Plough's Novel Oral Thrombin Receptor Antagonist Meets Primary Endpoint in Phase II Trial
Mar 20, 07
15:30 ET	New Cancer Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients
Mar 19, 07
10:27 ET	Schering-Plough to Webcast CEO Fred Hassan's Presentation at Lehman Brothers Tenth Annual Global Healthcare Conference
Mar 16, 07
08:00 ET	Media Advisory: ACC Updated Schedule
Mar 12, 07
09:00 ET	Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
08:32 ET	Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
03:01 ET	Schering-Plough to Acquire Organon BioSciences
Feb 28, 07
16:44 ET	Schering-Plough Announces Executive Changes in Research
08:00 ET	NASONEX(R) Earns the Arthritis Foundation Ease-of-Use Commendation
Feb 27, 07
09:57 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Feb 21, 07
11:09 ET	Schering-Plough to Webcast Presentation at Bear Stearns Healthcare Conference
Feb 13, 07
16:44 ET	James R. Nelson Retires from Schering-Plough
Feb 05, 07
18:16 ET	Schering-Plough Announces Executive Management Team Changes
Feb 02, 07
10:43 ET	Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
Jan 31, 07
11:03 ET	Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
08:00 ET	Schering-Plough Appoints Shaju Backer
Jan 29, 07
06:57 ET	Schering-Plough Reports Financial Results for 2006 Fourth Quarter, Full Year
Jan 26, 07
15:20 ET	Schering-Plough Corporation Mourns Death of Bruce R. Reid, Leader in Pharmaceutical Business
Jan 25, 07
02:00 ET	The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections
Jan 15, 07
07:52 ET	Schering-Plough Launches New National HomeAgain(TM) Proactive Pet Recovery Network
Jan 04, 07
08:00 ET	Schering-Plough and OraSure Technologies Sign Agreement for Development and Promotion of Rapid Point-Of-Care Oral Hepatitis C Test
Dec 22, 06
08:35 ET	Schering-Plough Schedules Conference Call, Webcast for 2006 Fourth Quarter and Full-Year Earnings
08:00 ET	Fulford (India) Limited Appoints K.G. Ananthakrishnan as Chief Operating Officer and President and Managing Director - Designate
Dec 19, 06
17:22 ET	Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Dec 15, 06
12:14 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
08:23 ET	Schering-Plough Announces Four Key Corporate Governance Actions
Dec 13, 06
16:30 ET	Schering-Plough Licenses Worldwide Rights to Pradefovir, Oral Hepatitis B Treatment In Development With Valeant Pharmaceuticals and Metabasis Therapeutics
Dec 05, 06
17:50 ET	Schering-Plough Enters Licensing Agreement to Market Prescription MiraLAX(R) Over-The-Counter
Nov 27, 06
08:00 ET	Schering-Plough Appoints Thierry Powis President Director, Indonesia
Nov 13, 06
11:59 ET	Schering-Plough to Webcast Presentation at 2006 Credit Suisse Health Care Conference
Nov 10, 06
17:21 ET	Schering-Plough CEO Calls on New Congress to 'Do What Is Right' for the Patient, Calls for 'Scorecards' to Rate Managed Care Performance
Nov 09, 06
02:00 ET	Noxafil(R) (Posaconazole) Oral Suspension Approved in European Union for Prevention of Invasive Fungal Infections
Nov 03, 06
07:00 ET	Newly-Published Data Showed LEVITRA(R) Treated Erectile Dysfunction Effectively at First Dose In Men With Certain Associated Cardiovascular Conditions
Nov 01, 06
11:57 ET	Schering-Plough Expanding Discovery Operations in Cambridge, Mass.
Oct 31, 06
08:00 ET	Schering-Plough Appoints Eduardo Cortes General Manager, Argentina
Oct 27, 06
08:30 ET	Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Oct 24, 06
08:30 ET	Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2006 Annual Meeting
Oct 23, 06
08:00 ET	Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Treatment of Oropharyngeal Candidiasis (OPC)
Oct 20, 06
07:01 ET	Schering-Plough Reports Financial Results for 2006 Third Quarter
Oct 12, 06
16:51 ET	Schering-Plough Chairman/CEO Fred Hassan Named New President of IFPMA
Oct 06, 06
02:00 ET	SUBOXONE(R) (Buprenorphine/Naloxone) Approved In European Union for Treatment of Opioid Dependence
Oct 03, 06
15:06 ET	Schering-Plough Schedules Conference Call and Webcast for Third Quarter 2006 Earnings
Sep 29, 06
13:30 ET	Efficacy of Once-Daily AVELOX(R) in Treating Complicated Intra-Abdominal Infections Highlighted in Two Clinical Data Presentations at ICAAC
Sep 22, 06
02:00 ET	European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Prevention of Invasive Fungal Infections
Sep 19, 06
12:06 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
08:59 ET	Thomas P. Koestler, Ph.D., Elected Head of Schering-Plough R&D
Sep 18, 06
08:00 ET	Schering-Plough Announces FDA Approval of NOXAFIL(R) (Posaconazole) for Prevention of Invasive Fungal Infections
Sep 08, 06
09:21 ET	Schering-Plough to Webcast Presentation at Bear Stearns 19th Annual Healthcare Conference
Aug 29, 06
10:45 ET	Schering-Plough Reaches Agreement With U.S. Attorney's Office for District of Massachusetts and U.S. Department of Justice
Aug 25, 06
15:26 ET	New CHILDREN'S CLARITIN(R) Grape Chewables Provide Non-Jittery, Non-Drowsy, All Day Relief for Kids' Allergy Symptoms
Aug 17, 06
16:00 ET	Vicriviroc Demonstrates Potent and Sustained Viral Suppression in ACTG Phase II Clinical Study in Treatment-Experienced HIV Patients
15:36 ET	Schering-Plough Receives Clarification of Its Rights for Golimumab
Aug 14, 06
08:30 ET	Schering-Plough Appoints Trevor Juniper General Manager, Schering-Plough China
01:36 ET	Schering-Plough Announces Global Agreement With Novartis to Develop Once-Daily Combination Therapy for Asthma and COPD
Jul 31, 06
13:30 ET	Schering-Plough Corporation Mourns Death of Jonathan R. Spicehandler, M.D., Retired R&D Head
07:30 ET	TEMODAL(R) Approved by Japan's Ministry of Health, Labor and Welfare for Patients With Malignant Gliomas
Jul 28, 06
08:59 ET	European Union's CHMP Adopts Positive Opinion for SUBOXONE(R) (Buprenorphine/Naloxone) for Treatment of Opioid Dependence
Jul 25, 06
08:30 ET	Study Shows Once-Daily AVELOX(R) as Effective as Multi-Dose Combination Therapy in Treating Complicated Intra-Abdominal Infections
Jul 24, 06
06:45 ET	Schering-Plough Reports Financial Results for 2006 Second Quarter
Jul 17, 06
08:32 ET	Schering-Plough Appoints John M. Carroll Vice President, Global Internal Audits
Jul 12, 06
08:30 ET	Schering-Plough Announces Executive Changes in Schering-Plough Research Institute
Jun 30, 06
12:34 ET	Jonathan R. Spicehandler, M.D. Retires From Schering-Plough
Jun 27, 06
14:15 ET	Schering-Plough Declares Quarterly Dividends On Common Shares and Mandatory Convertible Preferred Stock
Jun 21, 06
08:30 ET	Schering-Plough to Expand Its Presence in Latin America, Restructure Commercial Operations in Brazil
Jun 19, 06
13:07 ET	New Study Showed VYTORIN(R) (ezetimibe/simvastatin) Significantly More Effective than Crestor(R) (rosuvastatin) at Lowering LDL 'Bad' Cholesterol at All Doses Compared
Jun 09, 06
16:52 ET	Schering-Plough Schedules Conference Call and Webcast for Second Quarter 2006 Earnings
11:03 ET	Schering-Plough to Webcast CFO Robert J. Bertolini's Presentation at Goldman Sachs 27th Annual Global Healthcare Conference
06:00 ET	Most U.S. Men Unaware of Link Between Erectile Dysfunction and Common Health Problems Such as High Blood Pressure
Jun 06, 06
08:30 ET	Schering-Plough to Adopt Global Model for Planning, Managing Clinical Trials
Jun 01, 06
08:30 ET	Schering-Plough Announces Changes to Manufacturing Operations
May 23, 06
08:30 ET	Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
May 22, 06
08:21 ET	New DR. SCHOLL'S(R) DUAL ACTION FREEZE AWAY(TM) Brings Home Powerful Relief for Large, Stubborn Warts
May 19, 06
16:39 ET	Schering-Plough Announces Strategy and Action Plan on Social Issues
May 18, 06
08:30 ET	Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2006 Annual Meeting
May 15, 06
08:33 ET	Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
May 09, 06
14:19 ET	Goodbye to the Beach Battle: COPPERTONE KIDS(R) CONTINUOUS SPRAY SPF 50 Makes Sunscreen Application Easier for Parents
May 01, 06
15:53 ET	National Survey Reveals That Losing a Pet Can Be More Traumatic Than Losing a Job
Apr 28, 06
13:21 ET	Schering-Plough To Webcast Presentation At Deutsche Bank 31st Annual Health Care Conference
Apr 26, 06
02:00 ET	EU Label Change for INTRON(R) A (interferon Alfa-2b) Incorporates Long-Term Efficacy Data in Patients with Chronic Hepatitis C
Apr 20, 06
06:42 ET	Schering-Plough Reports Financial Results for First Quarter of 2006
02:00 ET	Schering-Plough Provides Update on Oral HCV Protease Inhibitor SCH 503034 Clinical Development Program for Hepatitis C
Apr 19, 06
16:33 ET	FDA Grants Fast Track Designation to Schering-Plough for its Thrombin Receptor Antagonist SCH 530348
Apr 18, 06
15:30 ET	Schering-Plough Patient Assistance Programs Offer Innovative Approach to Helping Patients Eligible for New Medicare Drug Benefit
Apr 12, 06
13:58 ET	Schering-Plough Appoints Raymond Russo Vice President, Global Cholesterol Marketing
Apr 07, 06
08:30 ET	AVELOX(R) Monotherapy as Effective as High-Dose Levofloxacin and Ceftriaxone Combination Therapy in Treating Patients With Severe Community-Acquired Pneumonia
Apr 04, 06
07:04 ET	CLARITIN(R) Partners With U.S. Men's National Soccer Team Member Landon Donovan and the American Youth Soccer Organization to Help Educate Allergy Sufferers
Mar 23, 06
08:00 ET	REMICADE(R) Is Approved in Australia for Treatment of Early Rheumatoid Arthritis and Psoriatic Arthritis
Mar 22, 06
07:01 ET	Study Shows LEVITRA(R) Treats Erectile Dysfunction Effectively in Men Taking Medications to Lower High Blood Pressure
Mar 20, 06
08:30 ET	Schering-Plough and PTC Therapeutics Announce Collaboration for Development of PTC's Preclinical Hepatitis C Compounds
Mar 17, 06
14:59 ET	Schering-Plough Announces Rodney Freeman Appointed Vice President, Global Supply Chain Management
Mar 16, 06
15:19 ET	Schering-Plough Announces Gregory J. Szpunar Appointed Group Vice President, Global Project Management, Schering-Plough Research Institute
Mar 15, 06
16:13 ET	Schering-Plough Announces Changes In Executive Finance Positions
09:05 ET	Schering-Plough Schedules Conference Call and Webcast for First Quarter 2006 Earnings
Mar 09, 06
04:01 ET	REMICADE(R) Is First Biologic Approved In European Union To Treat Ulcerative Colitis
Mar 07, 06
08:02 ET	Schering-Plough Intensifies Focus On Europe, Latin America And Asia-Pacific
Mar 06, 06
13:13 ET	Schering-Plough to Webcast CFO Robert J. Bertolini's Presentation at Lehman Brothers Ninth Annual Global Healthcare Conference
Mar 03, 06
18:15 ET	Schering-Plough Provides Update on Phase II Study of Vicriviroc
Feb 28, 06
12:41 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Feb 27, 06
08:01 ET	Schering-Plough Appoints Tudor Panu, M.D. as General Manager, Romania
Feb 24, 06
10:54 ET	Schering-Plough Promotes Gregory Oakes to Vice President, Corporate Accounts, U.S. Managed Markets
Feb 23, 06
08:00 ET	Schering-Plough Appoints Carlos G. Dourado
Feb 22, 06
08:46 ET	Schering-Plough Reports NOXAFIL(R) (Posaconazole) NDA Granted FDA 6-Month Priority Review for Prevention of Invasive Fungal Infections
Feb 13, 06
09:40 ET	Schering-Plough Reports Garenoxacin NDA Accepted for FDA Review
Feb 10, 06
08:01 ET	Schering-Plough Presents Vicriviroc Clinical Study Results at 13th Conference on Retroviruses and Opportunistic Infections
Feb 03, 06
09:26 ET	Schering-Plough to Webcast CFO Robert J. Bertolini's Presentation at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Feb 02, 06
07:30 ET	Health Canada Approves TEMODAL(R)(temozolomide) for Patients With Newly Diagnosed Glioblastoma Multiforme
Feb 01, 06
17:36 ET	FDA Approves CLARINEX-D(R) 12 HOUR (desloratadine 2.5mg/pseudoephedrine 120mg) Tablet Prescription Antihistamine with Decongestant for Seasonal Allergy Sufferers
Jan 30, 06
09:19 ET	Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
06:49 ET	Schering-Plough Reports Financial Results for 2005 Fourth Quarter, Full Year
02:00 ET	European Union CHMP Recommends Approval of REMICADE(R) for Treatment of Moderately to Severely Active Ulcerative Colitis
Jan 24, 06
08:32 ET	Head-To-Head Study Shows More Elderly Patients With Community-Acquired Pneumonia Recovered at Days 3 to 5 With AVELOX(R) (Moxifloxacin HCl) Compared to LEVAQUIN (Levofloxacin)
Jan 13, 06
02:30 ET	Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV
Jan 09, 06
17:48 ET	Schering-Plough Appoints Michael D. Boyd Vice President, Public Affairs, International
Jan 06, 06
12:18 ET	Schering-Plough Schedules Conference Call and Webcast for Fourth Quarter 2005 Earnings
Jan 03, 06
08:40 ET	Schering-Plough Announces Completion of cGMP Work Plan, Validation Certification Program Under FDA Consent Decree
Dec 22, 05
08:30 ET	Schering-Plough Announces PEG-INTRON(R) and REBETOL(R) Approved in Japan for Expanded Use in Treating Chronic Hepatitis C
Dec 21, 05
17:26 ET	Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Dec 15, 05
11:57 ET	Schering-Plough Board of Directors Announces New Election, Governance Measures
Dec 13, 05
08:30 ET	Schering-Plough Media Alert: Data on Schering-Plough Anti-Infectives to Be Presented at ICAAC
07:45 ET	Newly Published Study Demonstrates NASONEX(R) (Mometasone Furoate Monohydrate) Effective for Nasal Polyps With Once- or Twice-Daily Dose
Dec 12, 05
08:31 ET	New Study Shows NOXAFIL(R) (Posaconazole) Oral Suspension Significantly Reduced Invasive Fungal Infections, Aspergillosis, Compared to Standard Azole Antifungals in High-Risk Chemotherapy Patients
Dec 07, 05
16:47 ET	Schering-Plough Reports West Virginia Jury Finds in Favor of Company in Reimbursement Case
Dec 06, 05
12:34 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Dec 05, 05
16:34 ET	Schering-Plough Elects C. Robert Kidder to Board of Directors
Nov 30, 05
08:30 ET	FDA Approves New Indication for AVELOX(R) (moxifloxacin HCl) for Treatment of Complicated Intra-Abdominal Infections (cIAI)
Nov 16, 05
14:24 ET	Schering-Plough to Webcast Presentation at Credit Suisse First Boston Annual Health Care Conference
08:58 ET	Schering-Plough and ONCOMETHYLOME Sciences (OMS) Announce License and Collaboration Agreement For Use of OMS Pharmacogenomic Technology
Nov 15, 05
09:03 ET	HOMEAGAIN(R) Announces New Scanners Will Read All 125 kHz Microchips and Detect 134kHz Chips
Nov 14, 05
08:00 ET	Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity as Monotherapy and in Combination With PEG-INTRON(R) in Phase I Studies
Nov 12, 05
05:07 ET	PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates Consistently High Response Rates Across Patient Weight Groups in 'Real-Life' Treatment Setting
Nov 10, 05
12:02 ET	Schering-Plough Promotes Jeffrey Berkowitz To Group Vice President, U.S. Managed Markets
Nov 09, 05
08:30 ET	Schering-Plough Appoints New General Manager for the Netherlands
Nov 08, 05
11:34 ET	Data Show Morning Is the Most Difficult Time for Allergic Rhinitis Sufferers
11:32 ET	Data Show Nasal Congestion is Most Bothersome Symptom of Allergic Rhinitis
Nov 07, 05
08:05 ET	Data on Schering-Plough's Oral HCV Protease Inhibitor to be Presented for First Time at American Association for the Study of Liver Diseases (AASLD) Meeting
Nov 01, 05
14:54 ET	Schering-Plough Highlights R&D Pipeline and Product Portfolio at Analysts and Portfolio Managers Meeting
08:03 ET	Schering-Plough Submits New Drug Application In Japan for TEMODAL(R) In Treating Malignant Glioma
Oct 31, 05
03:15 ET	TEMODAL (R) After Surgery Significantly Improves Survival in Patients With Newly Diagnosed Glioblastoma Multiforme
Oct 27, 05
20:14 ET	Schering-Plough Discontinues Phase II Study of Vicriviroc in Treatment-Naive HIV Patients, Continues Phase II Study in Treatment-Experienced HIV Patients
02:00 ET	NOXAFIL(R) (Posaconazole) Oral Suspension Approved in European Union for Treatment of Invasive Fungal Infections
Oct 25, 05
03:01 ET	New Study Shows NOXAFIL(R) (Posaconazole) Oral Suspension Significantly Reduced Aspergillosis, Invasive Fungal Infections, Compared to Fluconazole, in Allogeneic Hematopoietic Stem Cell Transplant Recipients With Graft-Versus-Host Disease
Oct 24, 05
06:56 ET	Schering-Plough Reports 2005 Third Quarter Financial Results
Oct 21, 05
08:57 ET	Schering-Plough to Webcast 'R&D and Product Review' Meeting
Oct 19, 05
08:14 ET	New Study Will Determine If Comprehensive Anti-Platelet Therapy Can Prevent Heart Damage
Oct 12, 05
07:55 ET	Survey Finds Nearly Half of Persistent Asthma Sufferers Experience Their Worst Symptoms in The Evening and Nighttime
Oct 06, 05
06:01 ET	REMICADE(R) Receives Approval in European Union for Treatment of Moderate to Severe Plaque Psoriasis
Oct 05, 05
09:34 ET	Shorter Course of PEG-INTRON(R) and REBETOL(R) Combination Therapy Approved in European Union for Certain Hepatitis C Patients With Genotype 1 and Low Viral Load
Sep 28, 05
10:01 ET	Schering-Plough Announces Appointments in Global Pharmaceutical Business
Sep 21, 05
12:02 ET	Schering-Plough Appoints Leigh Ann Nicholson-Errico Vice President, Human Resources, Global Pharmaceutical Business - U.S.
Sep 20, 05
12:04 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Sep 14, 05
18:01 ET	Schering-Plough Schedules Conference Call and Webcast for Third Quarter 2005 Earnings
Sep 12, 05
09:56 ET	Schering-Plough To Webcast Presentation at Bear, Stearns 18th Annual Healthcare Conference
09:03 ET	Schering-Plough Named Among Top 10 In The Nation For Working Mothers
Sep 07, 05
08:30 ET	Schering-Plough Appoints New General Managers For Poland and The Philippines
Sep 06, 05
12:28 ET	Research Shows Patients With Allergic Rhinitis Prefer NASONEX(R) (Mometasone Furoate Monohydrate) To Flonase(R) for Scent and Taste
Sep 01, 05
16:32 ET	Schering-Plough to Provide Financial, Product Donations in Support of Hurricane Katrina Relief Effort
Aug 26, 05
08:40 ET	New Grape-Flavored CHILDREN'S CLARITIN(R) Syrup Delivers Powerful Allergy Relief With No Bitter Aftertaste
Aug 16, 05
08:09 ET	Schering-Plough Exercises Rights to Centocor's CNTO 148 Anti-TNF Agent
Aug 04, 05
20:00 ET	Schering-Plough and Sankyo Enter License Agreement for Olmesartan in Select Latin American Territories
Aug 02, 05
11:50 ET	Schering-Plough Appoints Jacqueline Crew, Ph.D., Vice President, Pharmaceutical Sciences Quality
Aug 01, 05
12:25 ET	Schering-Plough Appoints Paul Medeiros Vice President, Global Licensing
Jul 29, 05
09:21 ET	European Union's CHMP Adopts Positive Opinion For Shorter Course of PEGINTRON(R) and REBETOL(R) Combination Therapy For Certain Hepatitis C Patients With Genotype 1 and Low Viral Load
Jul 28, 05
13:07 ET	European Union's CHMP Adopts Positive Opinion for NOXAFIL(R) (posaconazole) Oral Suspension for Treatment of Invasive Fungal Infections
Jul 22, 05
16:01 ET	Schering-Plough to Acquire From Millennium Exclusive U.S. Marketing Rights for INTEGRILIN(R) (eptifibatide) Injection
13:11 ET	Schering-Plough Appoints John O'Mullane Group Vice President, Research and Development, Consumer Health Care
Jul 21, 05
06:53 ET	Schering-Plough Reports Financial Results for 2005 Second Quarter
Jul 15, 05
08:30 ET	FDA Approves Re-Formulated CLARINEX(R) (desloratadine) REDITABS(R) Tablets - Orally Disintegrating Prescription Antihistamine
Jul 06, 05
08:31 ET	Schering-Plough Expands Its Presence in Asia Pacific; Commercial Operations Opened in Korea and Pakistan
Jun 30, 05
08:31 ET	Schering-Plough Announces FDA Approval of AVELOX(R) (moxifloxacin HCl) for Treatment of Complicated Skin and Skin Structure Infections
Jun 29, 05
06:06 ET	NASONEX(R) (mometasone furoate monohydrate) Effective for Nasal Polyps with Once-Daily Dose
Jun 28, 05
16:03 ET	Schering-Plough Elects Thomas J. Colligan to Board of Directors
14:26 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Jun 23, 05
13:22 ET	Consumer Poll: Food Safety Confidence Will Improve With Mandatory National Animal Identification System
Jun 22, 05
17:05 ET	Study Shows 12 Weeks of Peginterferon Alfa-2b and Ribavirin Combination Therapy as Effective as 24 Weeks in Certain Hepatitis C Patients With Genotype 2 or 3 Virus
Jun 17, 05
15:50 ET	Schering-Plough Appoints Miguel Ribas General Manager, San Juan, Puerto Rico
Jun 10, 05
16:00 ET	Schering-Plough to Webcast Presentation at Goldman Sachs Global Healthcare Conference
06:00 ET	TEMODAL(R) Approved in European Union For Treatment of Newly Diagnosed Glioblastoma Multiforme
Jun 09, 05
12:02 ET	Schering-Plough Schedules Conference Call and Webcast For Second Quarter 2005 Earnings
May 31, 05
10:17 ET	Schering-Plough to Webcast CEO Fred Hassan's Presentation at Sanford Bernstein Strategic Decisions Conference
May 26, 05
16:30 ET	Schering-Plough Appoints Sumant Ramachandra, M.D., Ph.D., Vice President, Global Project Management, Schering-Plough Research Institute
16:26 ET	Schering-Plough Appoints Michael Perelman, M.D., Vice President, Global Project Management, Schering-Plough Research Institute
May 12, 05
10:15 ET	Data on PEG-INTRON(R) and REBETOL(R) Combination Therapy in Diverse Patient Populations to Be Presented at 2005 Digestive Disease Week (DDW) Meeting
May 06, 05
08:40 ET	Schering-Plough Appoints Jim Joyce as Country Manager, Ireland
May 03, 05
12:22 ET	Schering-Plough Announces Integration of West Coast Research Facilities
09:23 ET	Schering-Plough to Webcast CFO Robert J. Bertolini's Presentation at Deutsche Bank 30th Annual Health Care Conference
Apr 29, 05
09:32 ET	Schering-Plough Appoints Theo Nieuwenhuis Vice President, REMICADE Marketing
Apr 26, 05
16:12 ET	Schering-Plough Chairman/CEO Fred Hassan Reviews Progress in Action Agenda at Annual Shareholders Meeting
Apr 25, 05
19:14 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
08:54 ET	Schering-Plough Appoints John Howell as General Manager, Brinny, Ireland
Apr 22, 05
09:08 ET	European Union's CHMP Recommends Approval of TEMODAL(R) (Temozolomide) for the Most Common and Aggressive Form of Brain Cancer
Apr 21, 05
17:54 ET	Schering-Plough Reports Financial Results for 2005 First Quarter
Apr 20, 05
09:22 ET	Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
Apr 18, 05
04:00 ET	Clinical Benefits of Retreatment With PegIntron and Rebetol Combination Therapy Demonstrated in Difficult-to-Treat Hepatitis C Patients
Apr 14, 05
11:32 ET	Schering-Plough Appoints Urban Widen as General Manager, Sweden
Apr 05, 05
14:59 ET	Head of Schering-Plough Research Institute Named to New Jersey High-Tech Hall of Fame
Mar 31, 05
08:39 ET	FDA Approves ASMANEX(R) (mometasone furoate) for Once Daily Management of Asthma
Mar 28, 05
08:50 ET	Spring Allergies May Limit Attention Span and Impair Memory as Well as Cause Sniffles and Sneezes
Mar 22, 05
17:24 ET	CLARITIN(R) OTC Brand Sales Surpass $1 Billion Mark in U.S.
10:20 ET	Schering-Plough Appoints Susan G. Arbuck, M.D., Vice President, Global Clinical Development, Schering-Plough Research Institute
Mar 18, 05
14:20 ET	Schering-Plough Schedules Conference Call and Webcast for First Quarter 2005 Earnings
Mar 16, 05
11:31 ET	FDA Approves TEMODAR(R) (temozolomide) as Treatment for Patients With Newly Diagnosed Glioblastoma Multiforme
Mar 09, 05
17:02 ET	Breakthrough in Medical Research: New Chemotherapy Gives Hope to Brain Tumour Patients. A Clear Improvement in Survival Demonstrated for Glioblastoma
17:01 ET	Schering-Plough Reports Federal Appeals Court Rules in Favor of Company on K-DUR Antitrust Matter
Mar 04, 05
16:44 ET	Schering-Plough Appoints Elpidio Villarreal Vice President & Associate General Counsel, Litigation & Conflict Management
08:11 ET	FDA Approves CLARINEX-D(R) 24 HOUR Prescription-Strength Once-Daily Nondrowsy Antihistamine with a Decongestant
Mar 03, 05
13:30 ET	Schering-Plough Appoints James F. McLeod, M.D., Vice President, Global Clinical Development, Early Research & Experimental Medicine
Mar 02, 05
17:13 ET	Schering-Plough Appoints Christopher Kelly Vice President, Global Information Technology, Global Supply Chain/Global Quality Operations
Feb 28, 05
08:31 ET	Schering-Plough Appoints Guy Fekete General Manager, Animal Health, France
Feb 18, 05
10:55 ET	Schering-Plough Completes Acquisition of Most NeoGenesis' Assets
Feb 14, 05
13:10 ET	Schering-Plough Appoints Winston K.C. Lam Vice President And Associate General Counsel
Feb 11, 05
08:30 ET	Schering-Plough Appoints Dr. Armando Trujillo, Vice President and General Manager for Mexico Operations
Feb 10, 05
10:51 ET	Schering-Plough Appoints Charles Schultes Group Vice President, Finance, Global Pharmaceutical Business
Feb 09, 05
16:39 ET	Schering-Plough Mourns Death of Former Executive Steven C. Chellevold
Feb 08, 05
08:32 ET	NJPAC Adds Four Senior Executives to Board of Directors
Feb 07, 05
10:02 ET	Schering-Plough to Webcast CFO Robert J. Bertolini's Presentation at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Feb 03, 05
15:08 ET	Head of Schering-Plough Global Communications Named 2004 Communicator of the Year
Jan 25, 05
13:43 ET	Schering-Plough Declares Quarterly Dividends On Common Shares and Mandatory Convertible Preferred Stock
06:59 ET	Schering-Plough Reports Financial Results for 2004 Fourth Quarter, Full Year
Jan 20, 05
18:42 ET	Schering-Plough and NeoGenesis Announce Agreement
09:22 ET	Schering-Plough Appoints Jean-Louis Saillot, M.D., Vice President, Head of Global Pharmacovigilance
09:04 ET	Head of Schering-Plough Research Institute Named One of Most Powerful Black Executives In Corporate America
Jan 14, 05
15:11 ET	Schering-Plough Announces Sale of Madison, N.J. Site
Jan 12, 05
11:04 ET	Schering-Plough Announces Executive Changes in R&D
09:36 ET	Schering-Plough Launches Scent-Free Formulation of NASONEX(R) in U.S.
Jan 11, 05
09:02 ET	Winter Cold Season Reminder: Decongestants Pose Potential Risk to High Blood Pressure Sufferers
Jan 06, 05
19:15 ET	The Lancet Publishes First Study Showing Peginterferon Alfa-2b Effective as Monotherapy in the Treatment of Chronic Hepatitis B
Jan 05, 05
15:08 ET	Schering-Plough to Provide Support for Tsunami Relief Effort
Jan 03, 05
16:30 ET	Schering-Plough to Webcast Presentation At Morgan Stanley Pharmaceutical CEOs Unplugged Conference
Dec 20, 04
16:31 ET	Schering-Plough Schedules Conference Call and Webcast for Fourth Quarter 2004 Earnings
08:38 ET	Schering-Plough K.K. Completes Expansion Project for Shiga Plant in Japan
08:30 ET	Schering-Plough Appoints Gail S. Thornton Vice President, Global Communications, Europe, Canada, Middle East, Africa, Japan, Latin America and Far East Regions
Dec 15, 04
17:39 ET	NASONEX(R) Now FDA-Approved in United States for Nasal Polyps
Dec 14, 04
08:30 ET	Schering-Plough Appoints Ted Lithgow, Ph.D., Group Vice President, Commercial Development
Dec 10, 04
09:10 ET	Schering-Plough Announces PEG-INTRON(R) Now Available In Japan for Use In Combination With REBETOL(R) for Chronic Hepatitis C
Dec 09, 04
08:53 ET	Schering-Plough Appoints William J. Creelman Vice President, Tax; Daniel A. Nichols to Retire After 36 Years
Nov 24, 04
12:10 ET	Schering-Plough Announces New Instantly Dissolving CLARITIN(R) RediTabs(R) Now Available in Japan
11:41 ET	Schering-Plough Appoints Karl D. Salnoske Vice President and Chief Information Officer
Nov 10, 04
08:30 ET	Schering-Plough Appoints Pedro Barosa General Manager, Schering-Plough Portugal
Nov 05, 04
14:13 ET	Schering-Plough CEO Calls on President Bush for Courage To Take Tough Actions In Reforming Health Care System
Oct 31, 04
16:15 ET	Schering-Plough Reports Key Posaconazole Data Presented At ICAAC Annual Meeting
Oct 29, 04
18:11 ET	Schering-Plough Reports Comparative Pharmacokinetics and Pharmacodynamics Data for PEG-INTRON(R) and PEGASYS(R) in Hepatitis C Virus Infection
08:40 ET	Schering-Plough Reports FDA Grants Priority Review to TEMODAR(R) (Temozolomide) Supplemental New Drug Application for Gliomas (Brain Tumors)
Oct 27, 04
12:29 ET	PEG-INTRON(R) Studied in a Wide Range of Hepatitis C Patient Populations
Oct 22, 04
09:12 ET	Schering-Plough Announces PEG-INTRON(R) Approved in Japan for Use in Combination With REBETOL(R) for Chronic Hepatitis C
Oct 21, 04
06:43 ET	Schering-Plough Reports Financial Results for 2004 Third Quarter
Oct 20, 04
11:22 ET	Schering-Plough Appoints Mark Kerschner Vice President, Assistant Controller, Global Finance Operations
Oct 19, 04
08:30 ET	Schering-Plough Animal Health Corporation Announces FDA Approval of BANAMINE(R) for Use in Lactating Dairy Cattle
Oct 14, 04
08:30 ET	Remicade(R) Approved in European Union for Treatment of Psoriatic Arthritis
Oct 07, 04
16:41 ET	Schering-Plough Appoints Geri Brouwers General Manager of Schering-Plough Belgium/Luxembourg
Sep 28, 04
11:51 ET	Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
Sep 21, 04
14:14 ET	Schering-Plough Appoints Deborah A. Jorn Group Vice President, Global Allergy/Respiratory Marketing
08:27 ET	Schering-Plough Named Among 100 Best Companies in the Nation for Working Mothers
Sep 17, 04
10:53 ET	Schering-Plough Appoints Stephen G. Farrand, Ph.D., Vice President, Biotechnology Development
Sep 13, 04
01:31 ET	Schering-Plough Enters Into Strategic Alliance With Bayer
Sep 10, 04
09:58 ET	Schering-Plough Announces Promotions In Global Project Management, Schering-Plough Research Institute
Sep 09, 04
19:03 ET	Schering-Plough CEO Calls on Winner of Presidential Election to Adopt 4-Point Plan for Health Care Reform
16:02 ET	Schering-Plough Appoints Rene Imwinkelried, Ph.D., Vice President, Chemical Development
Sep 07, 04
16:38 ET	Schering-Plough to Webcast Presentation at Bear Stearns 17th Annual Healthcare Conference
Sep 01, 04
17:30 ET	FDA Approves CLARINEX(R) (Desloratadine) Syrup for Relief of Symptoms Associated With Indoor and Outdoor Allergies and Hives in Children
Aug 31, 04
12:01 ET	Schering-Plough Schedules Conference Call and Webcast for Third Quarter 2004 Earnings
Aug 26, 04
15:56 ET	Schering-Plough Announces FDA Approval of Scent-Free NASONEX(R) (mometasone furoate monohydrate) Nasal Spray, 50 mcg*
Aug 23, 04
08:31 ET	Schering-Plough Exercises Option to License ViroPharma's Intranasal Pleconaril
Aug 05, 04
10:57 ET	Schering-Plough Appoints Richard R. Nabb Vice President, Global Strategic Sourcing
Aug 04, 04
07:04 ET	Schering-Plough Announces Proposed Sale of $1.25 Billion of Mandatory Convertible Preferred Stock
Jul 30, 04
17:03 ET	European Union CHMP Recommends Approval of REMICADE(R) for Treatment of Psoriatic Arthritis
10:17 ET	Schering-Plough Reaches Agreement With U.S. Attorney's Office for Eastern District of Pennsylvania and U.S. Department of Justice
Jul 29, 04
16:28 ET	Schering-Plough Names Paul M. Graves Vice President, Global Staffing & Workforce Diversity
11:52 ET	Schering-Plough Appoints Lisa W. DeBerardine Vice President, Strategic Planning & Financial Forecasting
Jul 27, 04
09:17 ET	Schering-Plough Appoints Rodney W. Unsworth Group Vice President, Far East Region
Jul 23, 04
22:08 ET	Media Alert: Merck/Schering-Plough Pharmaceuticals to Conduct Call for Journalists Regarding U.S. Approval of VYTORIN
20:17 ET	Merck/Schering-Plough Pharmaceuticals to Conduct Conference Call and Webcast Regarding U.S. Approval of VYTORIN
Jul 21, 04
05:50 ET	Schering-Plough Reports Financial Results for 2004 Second Quarter
Jul 20, 04
08:49 ET	Schering-Plough Names Lennart Olving Vice President, Strategy Development and Operational Excellence, Global Supply Chain
Jul 13, 04
09:04 ET	Schering-Plough Reports posaconazole NDA Accepted For FDA Review
Jun 25, 04
16:46 ET	Schering-Plough Reschedules Conference Call and Webcast for Second Quarter 2004 Earnings
Jun 23, 04
08:07 ET	Schering-Plough Returns European Marketing Rights for INTEGRILIN(R) (EPTIFIBATIDE) Injection to Millennium
Jun 22, 04
08:03 ET	Toyama and Schering-Plough Execute License Agreement for Garenoxacin Quinolone Antibiotic
Jun 21, 04
14:42 ET	Schering-Plough Declares Regular Quarterly Dividend
11:24 ET	REMICADE(R) Approved in European Union for Treatment of Early Rheumatoid Arthritis
Jun 15, 04
15:10 ET	Schering-Plough Names Hans M. Vemer, M.D., Ph.D., Senior Vice President, Global Medical Affairs
10:00 ET	Schering-Plough Announces Executive Appointments In Its European Region
Jun 09, 04
13:11 ET	Schering-Plough Reaches Agreement With U.S. Securities and Exchange Commission
08:41 ET	Schering-Plough Schedules Conference Call and Webcast for Second Quarter 2004 Earnings
Jun 08, 04
17:49 ET	Schering-Plough CEO Fred Hassan Speaks on Important Pharmaceutical Industry Challenges
Jun 03, 04
08:29 ET	Jury Renders Decision in Schering-Plough Animal Vaccine Infringement Suit
May 28, 04
16:46 ET	New Data on Schering-Plough Oncology Products to be Presented at ASCO 2004 Annual Meeting in New Orleans
May 26, 04
17:01 ET	New Study Challenges Current Thinking About Varied Response to Hepatitis C Treatment in Different Racial Groups
08:32 ET	Schering-Plough to Develop Summit, N.J. Site for Offices and R&D, Consolidate Other N.J. Sites
May 25, 04
17:50 ET	Schering-Plough Announces Changes In Executive Finance Positions
May 14, 04
11:36 ET	Schering-Plough to Webcast CEO Fred Hassan Presentation to Washington Society of Investment Analysts
May 13, 04
08:59 ET	Nation's Top Medical Centers Seek Participants for Largest Study Comparing Leading Hepatitis C Treatments
May 12, 04
16:33 ET	Efficacy Data on PEG-INTRON(R) and REBETOL(R) in Wide Range of Hepatitis Patient Populations to Be Presented at Digestive Disease WEEK (DDW) Annual Meeting in New Orleans
May 11, 04
16:36 ET	Schering-Plough Announces Executive Promotions
May 03, 04
12:37 ET	Schering-Plough Reaches Agreement With Texas Attorney General's Office
08:49 ET	Schering-Plough Names Alex Kelly, R.Ph. Vice President, Investor Relations
Apr 30, 04
11:04 ET	Schering-Plough to Webcast Presentation At Deutsche Bank Securities' 29th Annual Health Care Conference
09:18 ET	Smart About the Sun: Coppertone(R) Declares May Sun Awareness Month
Apr 27, 04
15:25 ET	Schering-Plough Chairman/CEO Fred Hassan Reviews Progress, Vision for Future at Annual Shareholders Meeting
13:45 ET	Schering-Plough Declares Regular Quarterly Dividend
Apr 26, 04
16:14 ET	Schering-Plough Will Continue Providing Patient Assistance to Eligible Medicare Beneficiaries
15:01 ET	Schering-Plough Appoints Dr. Ian McInnes Senior Vice President, Global Supply Chain
Apr 23, 04
10:55 ET	European Union's CPMP Recommends Broader Indication for REMICADE(R) in Treatment of Early Rheumatoid Arthritis
Apr 22, 04
06:46 ET	Schering-Plough Reports Financial Results for 2004 First Quarter
Apr 21, 04
22:00 ET	Schering-Plough Submits New Drug Application (J-NDA) in Japan for PEG-INTRON(R) and REBETOL(R) Combination Therapy for Hepatitis C
Apr 20, 04
12:55 ET	Ever Think You Might Be Allergic to Your City?
09:52 ET	Religious Investors, Schering-Plough Announce Agreement on Actions Regarding Access to Prescription Drugs
Apr 14, 04
08:45 ET	Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
Apr 13, 04
08:51 ET	Schering-Plough's Global Animal Management, Inc. Introduces VeriSource(TM) Comprehensive Livestock Tracing and Tracking System
Apr 09, 04
09:35 ET	Schering-Plough Announces Warrick Pharmaceuticals Launches Generic Ribavirin Product in the United States
Mar 31, 04
01:00 ET	Toyama and Schering-Plough in Letter of Intent for Garenoxacin Quinolone Antibiotic
Mar 22, 04
11:29 ET	Schering-Plough Schedules Conference Call and Webcast for First Quarter 2004 Earnings
Mar 19, 04
08:30 ET	Schering-Plough and Merck Announce First Global Marketing Approval of Ezetimibe/Simvastatin Tablet in Mexico for Treatment of Elevated Cholesterol Levels
Mar 16, 04
09:02 ET	Schering-Plough Corporation Names Thomas J. Sabatino, Jr. Executive Vice President and General Counsel
Mar 04, 04
10:33 ET	Joseph C. Connors Plans to Leave Schering-Plough Corporation
Feb 17, 04
08:43 ET	Schering-Plough Announces Availability of PEG-INTRON REDIPEN(TM), Providing the Proven Efficacy of PEG-INTRON(R) in an Easy-to-use Pen
Feb 05, 04
16:41 ET	Schering-Plough Discontinues Phase III Clinical Study Of Sarasar(TM) (Lonafarnib) in Non-Small-Cell Lung Cancer
Jan 29, 04
08:41 ET	Schering-Plough to Webcast CEO Fred Hassan's Presentation at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Jan 27, 04
12:26 ET	Schering-Plough Declares Regular Quarterly Dividend
Jan 26, 04
06:33 ET	Schering-Plough Reports Financial Results for 2003 Fourth Quarter, Full Year
Jan 20, 04
08:47 ET	Schering-Plough Announces Availability of REBETOL(R) Oral Solution For Use in Treating Pediatric Hepatitis C
Jan 08, 04
08:38 ET	Schering-Plough Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2003 Earnings
Dec 18, 03
10:38 ET	Schering-Plough to Appeal FTC Ruling Involving Two K-DUR(R) Patent Litigation Settlements
Dec 16, 03
08:50 ET	Schering-Plough Reports on Collaboration With ALK-Abello
Dec 08, 03
18:29 ET	Noxafil(R) (Posaconazole Oral Suspension) Demonstrates Significantly Better Outcome In Patients With Life-Threatening Fungal Infection
Dec 04, 03
09:28 ET	Schering-Plough Announces Next Phase in Value Enhancement Initiative
Nov 28, 03
08:31 ET	Schering-Plough CEO Buys $4.68 Million of Company Common Stock
Nov 26, 03
13:22 ET	Schering-Plough Announces Completion of $2.4 Billion Senior Notes Offering
Nov 25, 03
12:41 ET	Schering-Plough and ViroPharma Enter Into Agreement for New Intranasal Formulation of Pleconaril
Nov 24, 03
08:54 ET	Study Shows Assessing Early Virologic Response (EVR) To PEG-INTRON(R) Weight-Based Therapy For Hepatitis C Can Reduce Treatment Duration and Costs
Nov 21, 03
19:02 ET	Schering-Plough Announces Pricing of Senior Notes Offering and Increase in Offering to $2.4 Billion
Nov 19, 03
16:45 ET	Schering-Plough to Raise $1.75 Billion From Sale of Senior Notes
15:52 ET	Schering-Plough Announces FDA Approval of CLARITIN Product in OTC Relief Of Hives
Nov 18, 03
11:32 ET	Chairman/CEO Fred Hassan Outlines Actions For Building 'The New Schering-Plough' at Analysts and Portfolio Managers Meeting
Nov 10, 03
07:26 ET	Schering-Plough Files 10-Q With 'Frequently Asked Questions'
Nov 05, 03
09:18 ET	Schering-Plough Appoints Robert Bertolini Chief Financial Officer
Oct 29, 03
16:20 ET	Schering-Plough Recommends Rejection of 'Mini-Tender' Offer From TRC Capital
16:13 ET	Schering-Plough Elects Philip Leder, M.D., of Harvard Medical School, to Board Of Directors
Oct 28, 03
12:33 ET	Schering-Plough Declares Regular Quarterly Dividend
09:18 ET	Study Finds REMICADE(R) (Infliximab) Treatment Increases Patients' Quality Of Life and Reduces Cost Burden of Ankylosing Spondylitis
Oct 27, 03
16:16 ET	Schering-Plough Reaches Settlement With Impax on CLARITIN-D(R) 24 Hour Patent Litigation
09:22 ET	Study Shows Molecular Size and Structure of PEG Interferon Molecules, As Used in PEG-INTRON(R), Affect Antiviral Activity in Vitro
Oct 24, 03
14:46 ET	Schering-Plough Reports Novel Investigational Protease Inhibitor Shows In Vitro Antiviral Activity in Hepatitis C Infection
09:16 ET	Schering-Plough Provides Grant Supporting Major New Hepatitis C Research and Education Initiative by American Academy of Family Physicians
Oct 23, 03
17:32 ET	Schering-Plough Named One of 20 Top Employers in Biotech and Pharmaceutical Industry Worldwide
16:16 ET	Schering-Plough Reaches Settlement With Andrx on CLARITIN-D(R) 24 Hour Patent Litigation
13:08 ET	PEG-INTRON(R) to be Featured in 54 Abstracts Presented at Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
09:27 ET	REMICADE(R) (infliximab) Gains EU Approval for Maintenance Dosing In Treatment of Fistulizing Crohn's Disease
Oct 22, 03
06:39 ET	Schering-Plough Reports Financial Results for 2003 Third Quarter
Oct 17, 03
16:14 ET	Schering-Plough Announces New Head of Global Supply Chain; Other Senior Global Manufacturing Appointments Also Announced
16:13 ET	Fred Hassan, Schering-Plough Chairman and CEO Announces Actions to Create Global, Integrated Supply Chain
09:18 ET	Schering-Plough Appoints Mary-Frances Faraji Vice President, Global Product Communications and Advocacy Development
Oct 14, 03
10:12 ET	Early Virologic Response (EVR) To PEG-INTRON(R) Individualized Weight-Based Therapy For Hepatitis C Evaluated In Study Published In Hepatology
08:35 ET	Novel Antifungal Agent Demonstrates Activity Against Coccidioidomycosis, A Potentially Deadly Fungal Disease
Oct 13, 03
08:53 ET	Schering-Plough Announces FDA Approval of PEG-INTRON REDIPEN(TM) For the Treatment of Chronic Hepatitis C
Oct 09, 03
18:26 ET	Schering-Plough Appoints Brent Saunders Senior Vice President, Global Compliance and Business Practices
Oct 01, 03
09:49 ET	Schering-Plough Reschedules Time of Conference Call and Webcast for Third Quarter 2003 Earnings
08:56 ET	Schering-Plough and Helsinn Healthcare SA Announce Licensing Agreement For Palonosetron in Select Global Markets
08:33 ET	Schering-Plough Says U.S. Attorney's Office in New Jersey Closes Previously Reported Investigation
Sep 29, 03
15:14 ET	Schering-Plough Schedules Conference Call and Webcast For Third Quarter 2003 Earnings
Sep 23, 03
10:49 ET	Schering-Plough to Initiate First Head-to-Head Study Of Leading Hepatitis C Therapies
08:57 ET	Schering-Plough Named Among 100 Best Companies in the Nation For Working Mothers
Sep 15, 03
08:51 ET	Schering-Plough Reports NOXAFIL(R) (Posaconazole Suspension) Clinical Data Presented at ICAAC Annual Meeting
Sep 12, 03
08:52 ET	Schering-Plough Appoints Michael DuBois Senior Vice President, Global Licensing
08:48 ET	Schering-Plough Appoints Jeffrey A. Winton Group Vice President, Global Communications
Sep 09, 03
12:33 ET	Schering-Plough Reports Settlement With Securities and Exchange Commission
Sep 03, 03
11:27 ET	Schering-Plough to Webcast CEO Fred Hassan's Presentation At Bear Stearns 16th Annual Healthcare Conference
Aug 22, 03
14:04 ET	Schering-Plough Files 8-K With 'Frequently Asked Questions' Outlines CEO Post -100-Day Review Investor Communications Plans
Aug 21, 03
18:21 ET	Schering-Plough Schedules Conference Call and Webcast
18:01 ET	Schering-Plough CEO Fred Hassan Completes First 100 Days, '360-Degree Review;' Announces Key Measures to Set Foundation for Turnaround
Aug 01, 03
15:53 ET	Schering-Plough Statement on Claritin(R) Patent Appeal
Jul 31, 03
09:56 ET	Schering-Plough Announces FDA Approval of Rebetol(R) for Use in Treating Pediatric Hepatitis C
Jul 25, 03
11:30 ET	European Union's CPMP Recommends Approval of REMICADE(R) For Maintenance Dosing for Fistulizing Crohn's Disease
Jul 23, 03
06:40 ET	Schering-Plough Reports Sales, Earnings for 2003 Second Quarter
Jul 22, 03
17:04 ET	Schering-Plough Appoints C. Ron Cheeley Senior Vice President, Global Human Resources
17:03 ET	Schering-Plough Research Institute Appoints Thomas Koestler Executive Vice President, Worldwide Regulatory Affairs, Worldwide Research Quality Assurance and Project Management
16:58 ET	Schering-Plough Reports NOXAFIL(R) Meets Primary Endpoint In Clinical Study In Invasive Fungal Infections
Jul 07, 03
07:48 ET	Ken Banta in Strategic Communications for Schering-Plough
07:47 ET	Schering-Plough's Geraldine U. Foster to Retire
07:46 ET	Schering-Plough Implements Organizational Changes in Discovery Research
07:44 ET	Stanley Barshay Appointed Chairman of Schering-Plough Consumer Health Care Business
07:43 ET	Schering-Plough Announces New Organizational Structure For Global Pharmaceutical Business
07:42 ET	Fred Hassan, Schering-Plough Chairman and CEO, Highlights Several New Action Steps in Turnaround Program
07:39 ET	Schering-Plough Comments on Earnings Outlook
Jun 27, 03
09:37 ET	Schering-Plough Schedules Conference Call and Webcast For Second Quarter 2003 Earnings
Jun 24, 03
12:54 ET	Schering-Plough Declares Regular Quarterly Dividend
May 30, 03
08:39 ET	Schering-Plough Provides Update on Previously Reported Investigation by U.S. Attorney for District of Massachusetts
May 29, 03
09:15 ET	Schering-Plough Announces CLARINEX(R) RediTabs(R) Launched For Indoor and Outdoor Allergies and Chronic Idiopathic Urticaria
May 21, 03
09:47 ET	REMICADE(R) (infliximab) Approved in European Union For Maintenance Dosing in Treatment of Crohn's Disease
09:05 ET	REMICADE(R) (infliximab) Approved in European Union For the Treatment of Ankylosing Spondylitis
May 20, 03
14:21 ET	Study Shows Liver Complications in Chronic Hepatitis C Associated with Obesity, Especially Around the Abdomen
May 13, 03
07:11 ET	Fred Hassan, New Schering-Plough Chairman and CEO, Announces Initial Action Steps in Turn-Around Program
07:07 ET	Carrie Cox Appointed Head of Schering-Plough Global Pharmaceutical Business
07:06 ET	Schering-Plough Reports Sales, Earnings for 2003 First Quarter
May 06, 03
17:15 ET	Schering-Plough Schedules Conference Call and Webcast for First Quarter 2003 Earnings
Apr 22, 03
16:27 ET	Hassan, New Schering-Plough CEO, Outlines Vision for Future At Annual Shareholders Meeting
13:38 ET	Schering-Plough Declares Regular Quarterly Dividend
Apr 20, 03
15:42 ET	Fred Hassan Elected CEO of Schering-Plough, To Be Elected Chairman of the Board
Apr 10, 03
11:48 ET	Schering-Plough Announces Agreement With Novartis to Co-Develop ASMANEX(R) And FORADIL(R) Combination Product for Asthma and COPD
Apr 08, 03
10:18 ET	Schering-Plough Sets Webcast For Annual Meeting of Shareholders
09:52 ET	Schering-Plough Sets Conference Call and Webcast for First Quarter 2003 Earnings
09:17 ET	Schering-Plough Reports FDA Grants Priority Review To REBETOL(R) for Treating Pediatric Hepatitis C
Apr 04, 03
12:53 ET	Schering-Plough Launches New Investor Relations Web Site
Apr 02, 03
12:07 ET	C-Reactive Protein Reduction Nearly Doubled by ZETIA(TM) (ezetimibe) Co-Administered With Simvastatin in Patients With High Cholesterol Compared to Simvastatin Alone, New Investigational Study Showed
Mar 26, 03
17:16 ET	Schering-Plough in Licensing Agreements With Geneva Pharmaceuticals and Teva Pharmaceuticals To Resolve U.S. Ribavirin Patent Disputes
Mar 18, 03
11:04 ET	CLARITIN(R) Paves the Road to Clarity This Spring With Non-Drowsy Allergy Relief
Mar 12, 03
15:09 ET	Schering-Plough Provides Update on Previously Reported Inquiry by Securities and Exchange Commission
Mar 05, 03
15:09 ET	Schering-Plough Provides 2003 Earnings Guidance, Withdraws Previous Earnings Estimates
11:35 ET	EZETROL(TM) (ezetimibe) Ready for Approval in the European Union
Feb 26, 03
08:58 ET	Interactive Cholesterol Information Web Site Launched
Feb 25, 03
13:23 ET	Schering-Plough Increases Litigation Reserves
09:04 ET	Schering-Plough Announces CLARINEX(R) Granted Six Months Additional Marketing Exclusivity, Updates Status of CLARINEX Formulations
Feb 21, 03
11:32 ET	REMICADE (R)(Infliximab) First Anti-TNF Agent to be Recommended For EU Approval for Treating Ankylosing Spondylitis
Feb 07, 03
15:39 ET	Schering-Plough in Licensing Agreement With Three Rivers Pharmaceuticals To Resolve U.S. Ribavirin Patent Dispute
Feb 05, 03
12:15 ET	Schering-Plough Files Debt Shelf Registration
Jan 28, 03
13:30 ET	Schering-Plough Declares Regular Quarterly Dividend
Jan 23, 03
06:56 ET	Schering-Plough Reports Sales, Earnings for 2002 Fourth Quarter and Full Year
Jan 21, 03
09:06 ET	Schering-Plough Announces Doliveux Resignation
09:05 ET	Schering-Plough Launches ASMANEX TWISTHALER In United Kingdom for Treatment of Asthma; Additional European Union Markets to Follow
Jan 14, 03
09:02 ET	Schering-Plough Research Institute Appoints Catherine Strader Executive Vice President, Discovery Research
08:56 ET	Schering-Plough Announces EU Approval of CAELYX(R) in Metastatic Breast Cancer
Jan 09, 03
17:57 ET	Schering-Plough Lowers 2002 Earnings Projection Due to Lower Fourth Quarter CLARITIN(R) Prescription Demand
Jan 08, 03
08:57 ET	Schering-Plough Sets Conference Call and Webcast For Fourth Quarter and Full Year 2002 Earnings
Dec 10, 02
16:40 ET	CLARITIN Hits Store Shelves Today; Only OTC Antihistamine Offering Once-Daily, Non-Drowsy Allergy Relief
Dec 02, 02
09:06 ET	Schering-Plough Announces PEG-INTRON(R) and REBETOL(R) Surpasses 150,000 Patients Treated Mark in United States
Nov 27, 02
16:11 ET	Schering-Plough Provides Update On CLARITIN(R) Over-The-Counter Approval
13:27 ET	Schering-Plough Announces Prescription-Strength CLARITIN(R) Approved For Over-The-Counter Sales
Nov 18, 02
10:45 ET	ZETIA(TM) Added to Ongoing Statin Treatment Provided 25 Percent Additional LDL Cholesterol Reduction vs. 4 Percent With Addition of Placebo, Study In 'American Journal of Cardiology' Showed
10:33 ET	New Data Show Hospital Adherence to Chest Pain Guidelines Reduced Risk of Death by Nearly Half
10:08 ET	Despite Treatment, Many Heart Disease Patients With Elevated Cholesterol Still Not Reaching Recommended Cholesterol Goals
Nov 13, 02
16:33 ET	Richard Jay Kogan to Retire as Schering-Plough CEO, President In April 2003 or Upon Appointment of Successor
Nov 12, 02
18:49 ET	Schering-Plough Reports on Investigation By U.S. Attorney For District of Massachusetts
Nov 04, 02
08:59 ET	Schering-Plough Reports Results of Clinical Studies of PEG-INTRON(R) and REBETOL(R) Combination Therapy for Hepatitis C at American Association for the Study of Liver Diseases Meeting
Nov 01, 02
02:30 ET	Schering-Plough and Novartis Sign Agreement Giving Schering-Plough U.S. Marketing Rights to FORADIL(R) AEROLIZER(R) for Respiratory Disease
Oct 31, 02
09:03 ET	Reckitt Benckiser to Reacquire From Schering-Plough U.S. Promotion Rights For SUBOXONE(R) and SUBUTEX(R)
Oct 30, 02
08:50 ET	Schering-Plough to Acquire From Novartis International Marketing Rights to Leucomax(R)
Oct 28, 02
07:01 ET	Merck/Schering-Plough Pharmaceuticals To Conduct Conference Call and Webcast Regarding FDA Approval of ZETIA(TM) (ezetimibe)
Oct 25, 02
23:44 ET	FDA Approves ZETIA(TM) (ezetimibe) for Cholesterol Reduction
21:43 ET	Merck/Schering-Plough Pharmaceuticals To Conduct Conference Call and Webcast Regarding FDA Approval of ZETIA(TM) (ezetimibe)
Oct 24, 02
07:33 ET	Schering-Plough Reports Sales, Earnings for 2002 Third Quarter
Oct 23, 02
08:53 ET	ALK-Abello and Schering-Plough Announce Agreement To Develop Tablet-Based Allergy Immunotherapy
Oct 22, 02
13:44 ET	Schering-Plough Declares Regular Quarterly Dividend
Oct 21, 02
09:31 ET	Website Upgrade Enhances Access to Melanoma Information
Oct 18, 02
13:02 ET	Schering-Plough Reports European Union's CPMP Recommends Approval of CAELYX(R) in Metastatic Breast Cancer
07:05 ET	Schering-Plough and Biogen Settle Royalty Payment Arbitrations
Oct 17, 02
10:19 ET	New Hepatitis C Website Offers Patients Credible, Easy-to-Access Information
09:39 ET	Merck/Schering-Plough Pharmaceuticals Announces Marketing Approval in Germany of Ezetimibe for Treatment of Elevated Cholesterol Levels
Oct 07, 02
19:27 ET	Schering-Plough Reports Inquiry by Securities and Exchange Commission
Oct 03, 02
22:44 ET	Schering-Plough Provides Outlook For Future Growth
Sep 24, 02
09:27 ET	Schering-Plough Announces Launch of PEG-INTRON(R) Pre-filled Pen in Europe
09:23 ET	Schering-Plough Sets Conference Call and Webcast For Third Quarter 2002 Earnings
09:17 ET	Schering-Plough Named Among 100 Best Companies for Working Mothers; Cited for Work/Life Initiatives by Working Mother Magazine
Aug 19, 02
08:45 ET	Schering-Plough Announces Resignation of Board Member
Aug 13, 02
17:57 ET	Schering-Plough's CEO and CFO Submit Certifications Affirming SEC Filings in 2002
Aug 08, 02
13:51 ET	Schering-Plough to Appeal District Court Ruling on CLARITIN(R) Patent
Jul 25, 02
07:07 ET	Schering-Plough Reports Sales, Earnings for 2002 Second Quarter
Jul 19, 02
08:45 ET	Schering-Plough Announces NASONEX(R) Indication Expanded to Include Children as Young as Age 2
Jul 16, 02
11:33 ET	Schering-Plough Reviews Pharmaceutical Research and Business Progress
Jul 11, 02
08:46 ET	Schering-Plough Sets Conference Call and Webcast For Second Quarter 2002 Earnings
Jul 08, 02
08:46 ET	Schering-Plough Announces Claritin(R) Approved in Japan
Jul 02, 02
15:41 ET	Schering-Plough Announces FTC Administrative Law Judge Finds K-Dur(R) Patent Litigation Settlements Lawful
08:59 ET	Schering-Plough to Webcast July 16 Meeting With Analysts and Portfolio Managers
Jun 28, 02
09:19 ET	Schering-Plough Announces CLARINEX REDITABS Approved For Indoor and Outdoor Allergies and Chronic Idiopathic Urticaria
Jun 25, 02
11:02 ET	Schering-Plough Declares Regular Quarterly Dividend
Jun 19, 02
19:00 ET	Schering-Plough Provides Update on Previously Reported Investigation
Jun 12, 02
15:48 ET	Schering-Plough Commends NIH for Consensus Statement On Management of Hepatitis C
Jun 04, 02
09:09 ET	Schering-Plough Announces European Union Broadens Desloratadine Indications to Indoor and Outdoor Allergies
Jun 03, 02
09:17 ET	Lemma Named Vice President, Corporate Information Technology And Chief Information Officer of Schering-Plough
May 28, 02
12:23 ET	Schering-Plough Research Institute Appoints Jensen Executive Vice President, Worldwide Clinical Research, Operations and Research Information Systems
May 21, 02
09:30 ET	Schering-Plough Reports Results of Clinical Studies of PEG-INTRON(R) and REBETOL(R) Combination Therapy for Hepatitis C at Digestive Disease Week Meeting
09:04 ET	Schering-Plough Research Institute Reports Farnesyl Transferase Inhibitor (FTI) Shows Promise in Advanced Solid Tumors
May 20, 02
08:55 ET	Schering-Plough Reports Results of CAELYX(R) Study in First-Line Treatment Of Metastatic Breast Cancer at ASCO
May 17, 02
07:02 ET	Schering-Plough Enters Into Consent Decree With FDA to Resolve U.S. Manufacturing Issues
May 15, 02
16:07 ET	Schering-Plough Statement on OCI Investigation, Status of Consent Decree Negotiations
Apr 25, 02
08:55 ET	Schering-Plough Announces European Union Approval of Desloratadine Syrup And Rapidly Disintegrating Tablets
Apr 23, 02
15:39 ET	Schering-Plough Annual Meeting Reviews Progress in Resolving Manufacturing Issues, Highlights New Products, Strong Research Pipeline
13:01 ET	Schering-Plough Increases Quarterly Dividend
Apr 22, 02
18:32 ET	Schering-Plough Announces FDA Advisory Committee Endorses CLARITIN(R) as OTC Treatment for Chronic Idiopathic Urticaria
Apr 18, 02
06:49 ET	Schering-Plough Reports Sales, Earnings For 2002 First Quarter
Apr 04, 02
09:46 ET	Schering-Plough Sets Conference Call and Webcast For First Quarter 2002 Earnings
Apr 02, 02
17:19 ET	Schering-Plough Reports On Status Of Consent Decree Negotiations
Mar 08, 02
01:00 ET	Schering-Plough Aims To Make CLARITIN(R) Premier Brand In OTC Category, Establish CLARINEX(R) As Premier Brand In Prescription Category
Mar 07, 02
08:59 ET	Pickett Appointed President of Schering-Plough Research Institute; Spicehandler Appointed Chairman of Schering-Plough Research Institute
Mar 06, 02
08:43 ET	Schering-Plough Announces European Union's CPMP Recommends Broadening Desloratadine Indications to Indoor and Outdoor Allergies
Mar 04, 02
08:38 ET	Schering Laboratories Begins CLARINEX(R) DTC Education Program
Feb 19, 02
08:47 ET	Schering-Plough Recalls Specific Lots of Claritin-D(R) 12 Hour Tablets
Feb 11, 02
08:45 ET	Schering-Plough Announces CLARINEX(R) (desloratadine) Tablets Approved for Allergic Rhinitis and Chronic Idiopathic Urticaria
Feb 06, 02
09:19 ET	Schering-Plough Corp and COR Therapeutics Announce JAMA Publication of ESPRIT Study; SGP Investor: Geraldine U. Foster (908) 298-7410
Jan 31, 02
09:02 ET	Schering-Plough Reports on Suits Filed Against Companies Seeking to Market Generic OTC Loratadine
Jan 24, 02
12:42 ET	Schering-Plough Corrects Conference Call ID Number Reviewing 2001 Fourth Quarter and Full-Year Earnings
06:51 ET	Schering-Plough Reports Sales, Earnings for 2001 Fourth Quarter and Full Year
Jan 22, 02
11:52 ET	Schering-Plough Declares Regular Quarterly Dividend
Jan 14, 02
08:42 ET	Schering-Plough Announces CLARINEX(R) (Desloratadine) Now Available Nationwide for Treatment of Seasonal Allergies
Jan 10, 02
08:35 ET	Schering-Plough Sets Conference Call and Webcast for Fourth Quarter and Full Year 2001 Earnings
Jan 07, 02
08:42 ET	Schering-Plough Announces European Union's CPMP Recommends Approval of Desloratadine Syrup and Rapidly Disintegrating Tablets
Dec 21, 01
19:00 ET	Schering-Plough Will Hold Informational Call/Webcast Today at 7 P.M.
18:15 ET	Schering-Plough Projects 2001 and 2002 Earnings, Highlights Business Progress, Strong Product Pipeline
18:14 ET	Schering-Plough Announces FDA Approval of CLARINEX(R) (Desloratadine) for Treatment of Seasonal Allergic Rhinitis
18:14 ET	Schering-Plough Announces Ongoing Negotiations with FDA for Consent Decree on Manufacturing Issues
Nov 21, 01
09:18 ET	Schering-Plough Announces REBETOL(R) Approval in Japan for Use in Combination With INTRON(R) A for Hepatitis C
Nov 12, 01
09:12 ET	Schering-Plough Reports Results of Clinical Studies of PEG-INTRON(TM) And REBETOL(R) Combination Therapy For Hepatitis C at American Association for the Study of Liver Diseases Meeting
Oct 23, 01
11:28 ET	Schering-Plough Declares Regular Quarterly Dividend
06:48 ET	Schering-Plough Reports Sales, Earnings for 2001 Third Quarter, First Nine Months
Oct 18, 01
13:20 ET	Robert P. Luciano Retires from Schering-Plough Board
Oct 09, 01
08:53 ET	Schering-Plough Named Among 100 Best Companies for Working Mothers; Cited for Work/Life Initiatives by Working Mother Magazine
08:37 ET	Schering-Plough Sets Conference Call and Webcast For Third Quarter 2001 Earnings
Oct 03, 01
08:12 ET	Schering-Plough Launches PEG-INTRON(TM) and REBETOL(R) Combination Therapy in U.S. for Chronic Hepatitis C
Aug 28, 01
08:39 ET	Schering/KEY Launches Interactive Web Site To Help People of All Ages Take Control of Their Asthma
Aug 13, 01
01:30 ET	Schering-Plough in Licensing Agreement with Roche Resolving Peginterferon Patent Disputes
Aug 09, 01
08:43 ET	Schering-Plough Announces European Union Approval Of Desloratadine For Treatment of Chronic Idiopathic Urticaria
Aug 08, 01
08:56 ET	Schering-Plough Announces PEG-INTRON(TM) and REBETOL(R) Combination Therapy Receives FDA Approval for Treatment of Chronic Hepatitis C
Aug 06, 01
08:45 ET	Schering-Plough and NeoGenesis Announce Research Collaboration To Discover Small-Molecule Drugs
Jul 26, 01
08:54 ET	Schering-Plough Announces FDA Approval to Market REBETOL(R) (Ribavirin, USP) Capsules Separately For Use in Combination With INTRON(R) A for Chronic Hepatitis C
Jul 25, 01
06:49 ET	Schering-Plough Reports Sales, Earnings for 2001 Second Quarter, First Half
Jul 11, 01
08:49 ET	Schering-Plough Sets Conference Call and Webcast For Second Quarter 2001 Earnings
Jul 03, 01
11:39 ET	Schering-Plough Again Ranked Among America's 50 Best Companies For Minorities
08:55 ET	Schering-Plough Submits U.S. Application For PEG-INTRON(TM) Redipen(TM) Single-Dose Delivery System
Jun 28, 01
11:11 ET	Schering-Plough Reports Expected 2001 Second Quarter Earnings Per Share
10:13 ET	Schering-Plough Reviews Pharmaceutical Research and Business Progress
Jun 27, 01
13:42 ET	Schering-Plough Announces Cesan Resignation
Jun 26, 01
11:52 ET	Schering-Plough Declares Regular Quarterly Dividend
Jun 22, 01
07:59 ET	Schering-Plough Provides Update on Manufacturing Issues And FDA Inspections of U.S. Manufacturing Facilities
Jun 18, 01
08:54 ET	Schering-Plough to Webcast June 28 Meeting With Analysts and Portfolio Managers
Jun 11, 01
08:32 ET	ESPRIT Study Results and Dosing Regimen Approved for Inclusion in U.S. Prescribing Information for INTEGRILIN(R) (eptifibatide) Injection
Jun 01, 01
08:37 ET	Kathryn C. Turner, Chairperson, CEO and President of Standard Technology, Inc., Elected to Schering-Plough Board of Directors
May 22, 01
09:07 ET	Schering-Plough Reports Interim Results of PEG-INTRON(TM) Plus REBETOL(R) Studies in Hepatitis C Patients at Digestive Diseases Week Meeting
May 21, 01
10:47 ET	Investigational Cholesterol Absorption Inhibitor, Ezetimibe, Significantly Reduced Levels of LDL Cholesterol or `Bad' Cholesterol in Patients, Study Results Showed
May 15, 01
09:10 ET	Schering-Plough Reports TEMODAR(R) (Temozolomide) Studies Presented at American Society of Clinical Oncology Annual Meeting
May 11, 01
17:14 ET	Schering-Plough Disagrees With FDA Advisory Panel's Recommendation Regarding CLARITIN(R) (Loratadine)
May 10, 01
08:47 ET	Schering-Plough K.K. Acquires Fujisawa Animal Health Business in Japan
May 09, 01
09:18 ET	Schering-Plough Announces European Union's CPMP Recommends Approval of Desloratadine for Chronic Idiopathic Urticaria
08:39 ET	Schering-Plough Opposes Insurance Company's Petition to Change Claritin(R) (loratadine) Prescription Status
May 08, 01
08:46 ET	Schering-Plough Submits New Drug Application (J-NDA) in Japan For Rebetol(R) In Combination With Interferon Alfa-2b For Hepatitis C
Apr 24, 01
15:12 ET	Schering-Plough Annual Meeting Highlights Worldwide Performance, Commitment to Resolving Manufacturing Issues
12:52 ET	Schering-Plough Increases Quarterly Dividend
Apr 17, 01
06:58 ET	Schering-Plough Reports Sales, Earnings for 2001 First Quarter
Apr 16, 01
08:38 ET	Schering-Plough Applies for Broader CLARINEX(TM) Indication In United States for Treatment of Allergic Rhinitis
Apr 05, 01
08:52 ET	Schering Laboratories and SKOLAR Announce Online Continuing Medical Education for Physicians
Apr 03, 01
14:59 ET	Schering-Plough Sets Conference Call For First Quarter 2001 Earnings
Apr 02, 01
15:34 ET	Schering-Plough to Challenge FTC Administrative Complaint Involving Two Patent Litigation Settlements
Mar 29, 01
09:04 ET	Medarex and Schering-Plough Announce Research Alliance To Develop Human Antibody Therapeutics
Mar 28, 01
08:45 ET	Schering-Plough Announces European Union Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Hepatitis C
Mar 23, 01
08:47 ET	Schering-Plough Reports FDA Assigns Priority Review Status to PEG-INTRON(TM) And REBETOL(R) Application for Chronic Hepatitis C
Feb 15, 01
16:36 ET	Schering-Plough Reports on Manufacturing Issues and FDA Inspections of U.S. Facilities, Comments on Earnings Impact
Feb 06, 01
08:39 ET	Schering-Plough Submits U.S. Application for PEG-INTRON(TM) and REBETOL(R) For Use as Combination Therapy for Chronic Hepatitis C
Feb 05, 01
08:48 ET	European Union Approves REMICADE(R) For Broader Indication in Treatment of Rheumatoid Arthritis
Jan 25, 01
22:04 ET	Schering-Plough Reports Desloratadine Receives FDA 'Approvable' Letter
06:53 ET	Schering-Plough Reports Sales, Earnings for 2000 Fourth Quarter and Full Year
Jan 23, 01
11:20 ET	Schering-Plough Declares Regular Quarterly Dividend
Jan 22, 01
09:44 ET	Schering-Plough Announces FDA Approval of Peg-Intron(TM) For Treatment of Chronic Hepatitis C
Jan 18, 01
08:47 ET	Schering-Plough Submits Two New Marketing Applications For AERIUS(TM)/NEOCLARITYN(TM) in European Union
Jan 16, 01
08:56 ET	Schering-Plough Announces European Union Approval Of AERIUS(TM)/NEOCLARITYN(TM) for Treatment of Seasonal Allergies
Jan 08, 01
09:05 ET	Schering-Plough, COR and Genentech Announce U.S. Collaboration For INTEGRILIN(R), TNKase(TM) and Activase(R)
Dec 21, 00
09:11 ET	Schering-Plough Submits U.S. Marketing Application For Desloratadine Rapidly Disintegrating Tablets
Dec 20, 00
08:51 ET	Schering-Plough Announces European Union's CPMP Recommends Approval of PEGINTRON(TM) and REBETOL(R) As Combination Therapy for Treatment of Hepatitis C
Dec 14, 00
08:53 ET	Schering-Plough Submits Supplemental NDA to Market REBETOL(R) (Ribavirin, USP) Capsules Separately for use in Combination Therapy for Chronic Hepatitis C
Dec 13, 00
08:43 ET	Schering-Plough Submits U.S. Marketing Applications For Two New Formulations of Desloratadine
Dec 08, 00
08:47 ET	Schering-Plough to Build Four New Facilities in Singapore; $450 Million (U.S.) Expansion Boosts Investment in Singapore to $750 Million (U.S.)
Dec 07, 00
08:53 ET	Schering-Plough Announces Claritin(R) Syrup Receives U.S. Marketing Approval For Children as Young as 2 Years Old
Dec 06, 00
08:45 ET	Schering-Plough Announces Marketing Approval in Canada Of ASMANEX(R) TWISTHALER(TM) for Treatment of Asthma
Nov 28, 00
19:09 ET	Schering-Plough Fair Disclosure Statement
Nov 15, 00
11:38 ET	Schering-Plough and ICN Pharmaceuticals Announce Strategic Licensing Agreement
Oct 30, 00
13:08 ET	Schering-Plough Reports Phase III PEG-INTRON(TM) Plus REBETOL(R) Results at American Association For The Study of Liver Diseases Meeting
Oct 26, 00
08:52 ET	Schering-Plough Announces European Union Approval Of Caelyx(R) for Advanced Ovarian Cancer
Oct 25, 00
09:21 ET	David H. Komansky, Chairman/CEO of Merrill Lynch, Elected to Schering-Plough Board of Directors
Oct 24, 00
11:29 ET	Schering-Plough Declares Regular Quarterly Dividend
06:59 ET	Schering-Plough Reports Sales, Earnings for 2000 Third Quarter, First Nine Months
Oct 18, 00
12:43 ET	Schering-Plough Marks Opening of New World Headquarters in Kenilworth, N.J.
Oct 16, 00
10:44 ET	ECOG Study in High-Risk Malignant Melanoma Confirms Survival Advantage For Schering-Plough's INTRON(R) A
Oct 10, 00
17:13 ET	European Union's CPMP Recommends Approval of REMICADE(R) for Broader Indication in Treatment of Rheumatoid Arthritis
16:07 ET	Schering-Plough Announces European Union's CPMP Recommends Approval of Desloratadine for Seasonal Allergies
Oct 04, 00
08:39 ET	Schering-Plough Announces NASONEX(R) Receives U.S. Patent Protection to 2017
Oct 03, 00
07:54 ET	Schering-Plough Reiterates Earnings Projection for 2000
Sep 06, 00
11:04 ET	Schering-Plough Announces U.S. Patent and Trademark Office Confirms Validity of Loratadine Compound Patent
11:04 ET	Schering-Plough Appoints Curnutte President, DNAX Research Institute; Vice President, Schering-Plough Research Institute
Sep 05, 00
09:43 ET	Schering-Plough Among 100 Best Companies for Working Mothers; Cited for Work-Life Initiatives by Working Mother Magazine
08:48 ET	Schering-Plough Submits U.S. Application for Desloratadine for Treatment of Chronic Idiopathic Urticaria
Aug 16, 00
08:15 ET	Schering-Plough Announces Claritin(R) Granted Six Months Additional Marketing Exclusivity for Pediatric Studies
Aug 15, 00
15:20 ET	Schering-Plough Ranked Among World's 100 Best-Managed Companies
Jul 25, 00
07:17 ET	Schering-Plough Reports Sales, Earnings for 2000 Second Quarter, First Half
Jul 13, 00
11:06 ET	Schering-Plough Announces Agreement to Purchase Summit, N.J. Research and Office Facility From Novartis
Jul 12, 00
11:31 ET	Schering-Plough Reports 2000 Second Quarter Earnings Per Share, Reviews Pharmaceutical Research and Business Progress
Jul 10, 00
11:46 ET	Schering-Plough and Texas Biotechnology Form Alliance to Discover, Develop VLA-4 Antagonist Drugs to Treat Asthma
Jun 30, 00
09:16 ET	Schering-Plough Announces European Union's CPMP Recommends Approval Of CAELYX(R) for Advanced Ovarian Cancer
Jun 27, 00
08:33 ET	Schering-Plough and Merck Announce Completion of Federal Government Review of Cholesterol-Management and Respiratory Agreements
Jun 19, 00
09:28 ET	Schering-Plough Declares Regular Quarterly Dividend
May 30, 00
09:20 ET	Schering-Plough Announces European Union Approval Of PEGINTRON(TM) for Treatment of Hepatitis C
May 25, 00
11:39 ET	Schering-Plough Announces U.S. District Court Orders Pfizer/UCB to Stop Promoting Zyrtec(R) as Nonsedating
May 23, 00
08:07 ET	Schering-Plough and Merck Announce Agreements to Develop New Products In Cholesterol-Management and Respiratory Areas
May 05, 00
13:38 ET	Schering-Plough Discontinues ZIRACIN(TM) Clinical Development
May 01, 00
12:12 ET	Schering-Plough Reports Results of PEG-INTRON(TM) Phase III Studies at European Association for The Study of The Liver (EASL) Meeting
Apr 25, 00
14:58 ET	Schering-Plough Annual Meeting Highlights Worldwide Performance, Commitment to Pharmaceutical Research
12:04 ET	Schering-Plough Increases Quarterly Dividend
Apr 20, 00
07:21 ET	Schering-Plough Reports Sales, Earnings for 2000 First Quarter; 2000 First Quarter Diluted Earnings Per Share up 17% to 42 Cents
Mar 29, 00
13:11 ET	Schering Laboratories Recalls Certain Aerosol Inhalers Manufactured Prior to Sept. 30, 1999
08:15 ET	Schering-Plough Completes $1 Billion Share Repurchase Program, Initiates New $1.5 Billion Share Repurchase Program, Reiterates 2000 Earnings Projection
Mar 22, 00
16:43 ET	Schering-Plough Announces Arbitrators Rule in Company's Favor In Royalty Dispute with Biogen
Mar 03, 00
11:55 ET	Schering-Plough and Novo Nordisk Conclude U.S. Co-Promotion Agreement for Prandin(TM) and Diabetes Care Products
Feb 24, 00
07:21 ET	Schering-Plough Sees Strong Earnings Per Share Growth in 2000, Projects Completion Of Stock Buyback Program
Feb 23, 00
18:46 ET	European Union's CPMP Recommends Approval of REMICADE(TM) for Treatment of Rheumatoid Arthritis
Feb 22, 00
13:39 ET	Schering-Plough Announces European Union's CPMP Recommends Approval of PEGINTRON(TM) for Treatment of Hepatitis C
Feb 08, 00
18:16 ET	Study Finds Absence Of Growth Suppression In Children With Perennial Allergic Rhinitis After One Year Of Treatment With Nasonex(R)
Feb 04, 00
08:17 ET	INTEGRILIN(R) (Eptifibatide) Injection Stent Study Halted Early Due To Positive Results
Feb 02, 00
07:22 ET	Schering-Plough Reports Sales, Earnings for 1999 Full Year And Fourth Quarter
Jan 27, 00
08:43 ET	Schering-Plough Submits Centralized Type II Variation In EU for CAELYX(R) for The Treatment of Advanced Ovarian Cancer
Jan 25, 00
10:55 ET	Schering-Plough Declares Regular Quarterly Dividend
Jan 05, 00
08:48 ET	Schering-Plough Submits U.S. Application for Peg-Intron(R) for the Treatment Of Chronic Hepatitis C
Dec 16, 99
08:37 ET	Schering-Plough Licenses Cedax(R) Marketing Rights to DJ Pharma
Dec 07, 99
08:37 ET	Eugene McGrath, Chairman/CEO of Con Edison, Elected to Schering-Plough Board of Directors
Dec 02, 99
17:35 ET	Schering/Key Issues Nationwide Recall of Five Lots of Vanceril(R) Double Strength Inhalation Aerosol Convenience Pack
08:40 ET	Schering-Plough Announces U.S. Marketing Approval of NASONEX(R) Nasal Spray for Children as Young as 3 Years of Age
Nov 09, 99
10:50 ET	Schering-Plough Reports Results of Clinical Studies of Rebetron(TM) Combination Therapy For Hepatitis C at American Association for the Study of Liver Diseases Meeting
Nov 03, 99
09:07 ET	Schering-Plough Announces European Union Approves Pediatric Use of NASONEX(R) Nasal Spray
Oct 28, 99
12:13 ET	Schering-Plough Researchers Identify Promising Drug Targets in Hepatitis C Virus
08:48 ET	Schering-Plough and Atherogenics in Agreement to Develop Cardiovascular Drugs
Oct 26, 99
13:17 ET	Arthur F. Weinbach, Chairman/CEO of ADP, Elected to Schering-Plough Board of Directors
11:44 ET	Schering-Plough Declares Regular Quarterly Dividend
08:38 ET	Schering-Plough Files U.S. Application for Desloratadine For Treatment of Seasonal Allergic Rhinitis
Oct 20, 99
07:18 ET	Schering-Plough Reports Sales, Earnings For 1999 Third Quarter, First Nine Months
Oct 13, 99
12:55 ET	Schering-Plough Research Institute Reports on ASMANEX(R) Inhaler; Presentations at European Respiratory Society Congress
Oct 07, 99
09:18 ET	Schering-Plough in Agreement to Acquire BAIN DE SOLEIL(R) Sun Care Line From Pfizer
Sep 20, 99
09:23 ET	Doliveux Appointed President of Schering-Plough International
Sep 09, 99
20:12 ET	Warrick Pharmaceuticals Issues Nationwide Recall on One Lot of Albuterol Inhaler Aerosol
Sep 07, 99
02:30 ET	Schering-Plough and British Biotech Announce Agreement to Develop Matrix Metalloproteinase Inhibitors (MMPIs) for Cancer
Aug 26, 99
11:09 ET	Schering-Plough Announces European Union Approval of TEMODAL(R) for Recurrent Anaplastic Astrocytoma
Aug 11, 99
16:42 ET	Schering-Plough Announces FDA Approval of TEMODAR(TM) (Temozolomide) Capsules For Patients With Refractory Anaplastic Astrocytoma
Jul 21, 99
07:25 ET	Schering-Plough Reports Sales, Earnings For 1999 Second Quarter, First Half
Jul 06, 99
08:16 ET	Schering-Plough Announces EU Approval of INTEGRILIN(R) for the Prevention of Early Myocardial Infarction in Patients Presenting with Unstable Angina or Non-Q-Wave Myocardial Infarction
Jul 01, 99
18:33 ET	Schering-Plough Ranked Among 50 Best Companies for Minorities; Cited for Diversity Programs for Asians, Blacks and Hispanics
Jun 24, 99
12:55 ET	Schering-Plough Offers Earnings Forecast for 1999 Second Quarter and Full Year, Reviews Business and Research Progress
Jun 22, 99
11:21 ET	Schering-Plough Declares Regular Quarterly Dividend
May 26, 99
08:36 ET	Schering-Plough Announces European Union's CPMP Recommends Approval of TEMODAL(R) for Treating Brain Tumors
May 20, 99
17:20 ET	Schering-Plough Healthcare Products Successfully Defends Trade Dress
May 17, 99
08:32 ET	Schering-Plough Reports Results of Temozolomide Studies Presented at American Society of Clinical Oncology Annual Meeting
May 10, 99
08:07 ET	Schering-Plough Announces EU Approval of REBETOL(R) in Combination With Interferon Alfa-2b for Chronic Hepatitis C
Apr 27, 99
14:58 ET	Schering-Plough Annual Meeting Highlights Worldwide Performance, Commitment to Pharmaceutical Research
12:28 ET	Schering-Plough Increases Quarterly Dividend
Apr 20, 99
06:57 ET	Schering-Plough Reports Sales, Earnings For 1999 First Quarter; 1999 First Quarter Diluted Earnings Per Share up 20% to 36 Cents
Mar 30, 99
08:34 ET	Schering-Plough Submits Centralized Type II Variation in EU for TEMODAL(R) as Treatment for Brain Tumors, Malignant Melanoma
Mar 11, 99
11:43 ET	Allergy Sufferers Get the Itch for Relief
Mar 09, 99
08:25 ET	Schering-Plough Submits U.K. Marketing Application for ASMANEX(R) Twisthaler(TM) For Asthma
Feb 26, 99
07:40 ET	Schering-Plough Announces EU'S CPMP Recommends Approval Of Integrilin(TM) for Acute Coronary Syndrome
07:39 ET	Schering-Plough Announces European Union's CPMP Recommends Approval of Rebetol(R) with Interferon Alfa-2b for Relapse and Naive Hepatitis C Patients
Feb 03, 99
08:27 ET	Schering-Plough Submits Supplemental NDA for NASONEX(R) Nasal Spray For Pediatric Use
Jan 28, 99
08:18 ET	Schering-Plough Announces European Union Approval of TEMODAL(R) for Recurrent Glioblastoma Multiforme
Jan 26, 99
10:46 ET	Schering-Plough Declares Regular Quarterly Dividend
07:05 ET	Schering-Plough Reports Sales, Earnings for 1998 Full Year and Fourth Quarter
Jan 12, 99
15:44 ET	Schering-Plough Announces FDA Advisory Committee Recommends Approval of Temodal(R) for Recurrent Anaplastic Astrocytoma
Dec 10, 98
08:00 ET	Schering-Plough Announces FDA Approval of Rebetron(TM) Combination Therapy for Previously Untreated Hepatitis C Patients
Dec 09, 98
18:02 ET	Schering-Plough Announces FDA Approval of Rebetron(TM) Combination Therapy for Previously Untreated Hepatitis C Patients
08:09 ET	Astra in Agreement with Schering-Plough to Reacquire LOSEC(R) and PERFUDAL(R)/PREVEX(R) Rights in Italy, Spain
Dec 04, 98
17:21 ET	Schering Laboratories Receives Approval For New Oval-Shaped CLARITIN(R)-D 24 Hour Extended Release Tablets
Dec 02, 98
08:30 ET	Schering-Plough Submits NDA for Mometasone Furoate Inhalation Powder for Treatment of Asthma
Nov 23, 98
08:45 ET	Schering-Plough Reports Findings of p53 Gene Therapy Studies at Conference On Gene Therapy of Cancer Annual Meeting
Nov 19, 98
08:44 ET	Studies Published in The New England Journal of Medicine Report Results for Rebetron(TM) Combination Therapy in Previously Untreated and Relapse Hepatitis C Patients
Nov 10, 98
08:46 ET	Schering-Plough Reports Results of Clinical Studies of REBETRON(TM) Combination Therapy for Hepatitis C at American Association for the Study of Liver Diseases Meeting
Oct 27, 98
11:41 ET	Schering-Plough Declares Regular Quarterly Dividend
08:42 ET	Schering-Plough and Genzyme Molecular Oncology in Licensing Agreement For P53 Gene Therapy Patent Rights
Oct 26, 98
10:48 ET	Schering-Plough Announces European Union's CPMP Issues Unanimous Opinion Recommending Approval of TEMODAL(R) For Treating Brain Tumors
Oct 20, 98
07:09 ET	Schering-Plough Reports Sales, Earnings for 1998 Third Quarter, First Nine Months
Oct 01, 98
08:34 ET	Schering-Plough and Incyte Pharmaceuticals Enter Into Genomic Data Collaboration
Sep 23, 98
10:01 ET	Schering-Plough Board of Directors Elects Richard Jay Kogan Chairman of Board And CEO, Raul E. Cesan as President and Chief Operating Officer
07:59 ET	Schering-Plough Board of Directors Declares 2-For-1 Stock Split
Sep 15, 98
08:36 ET	Schering-Plough Presents TEMODAL(R) Brain Cancer Studies At European Association for Neuro-Oncology Meeting
Aug 25, 98
08:26 ET	Schering-Plough Receives U.S. Marketing Approval for INTRON(R) A Pediatric Use in Chronic Hepatitis B
Aug 18, 98
08:24 ET	Schering-Plough Submits NDA for Temodal(R) as Treatment for Brain Tumors, Malignant Melanoma
Aug 17, 98
04:33 ET	Schering-Plough Reports Priority Review Status Assigned to sNDA for Use of REBETRON(TM) Combination Therapy in Treatment-Naive Hepatitis C Patients
Aug 12, 98
18:53 ET	Landmark Acute Coronary Syndrome Trial Shows Integrilin(TM) (Eptifibatide) Reduces Combined Rate of Death or Heart Attack Regardless of Patient Management Strategy
Jul 21, 98
07:22 ET	Schering-Plough Reports Sales, Earnings For 1998 Second Quarter, First Half
Jul 16, 98
14:06 ET	Schering-Plough Acquires ICN's European Rights to Oral Ribavirin for Treatment of Hepatitis C
Jul 09, 98
08:30 ET	Schering-Plough and Immune Response in Agreement to Develop Hepatitis Gene Therapy Products
Jul 08, 98
13:12 ET	Schering-Plough Reports Second Quarter 1998 EPS, Provides Earnings Forecast for Full Year 1998, and Reviews Business and Research Progress
Jul 07, 98
14:20 ET	Joan Lunden Teams Up With Schering Corporation to Fight Seasonal Allergy Symptoms
Jun 26, 98
12:22 ET	Kirn-Slaboszewicz Appointed President, Schering-Plough HealthCare Products; Bryce to Retire at Year-end
Jun 23, 98
11:38 ET	Schering-Plough Declares Regular Quarterly Dividend
Jun 18, 98
16:56 ET	Schering-Plough in Agreements Resolving Alpha Interferon Patent Dispute
Jun 16, 98
10:50 ET	Supplemental NDA Submitted for Use of REBETRON(TM) Combination Therapy in Treatment-Naive Hepatitis C Patients
09:50 ET	Schering-Plough Submits Supplemental NDA for Use of REBETRON(TM) Combination Therapy in Treatment-Naive Hepatitis C Patients
Jun 03, 98
12:14 ET	Schering-Plough Announces FDA Approval of REBETRON(TM) Combination Therapy for Chronic Hepatitis C
May 18, 98
17:00 ET	INTEGRILIN(TM) -- First Heart Drug in Class Approved For Both Acute Coronary Syndrome and Angioplasty
08:20 ET	Schering-Plough Announces Phase III Results of INTRON(R) A and REBETOL(TM) Combination Therapy In Treatment-Naive Hepatitis C Patients
May 04, 98
17:13 ET	FDA Advisory Committee Concludes Schering-Plough's INTRON(R) A and REBETOL(TM) Combination Therapy Safe and Effective for Hepatitis C
17:13 ET	FDA Advisory Committee Concludes Schering-Plough's INTRON(R) A and REBETOL(TM) Combination Therapy Safe and Effective for Hepatitis C
Apr 28, 98
15:05 ET	Schering-Plough Annual Meeting Highlights Worldwide Performance, Commitment to Pharmaceutical Research
12:37 ET	Schering-Plough Increases Quarterly Dividend
Apr 21, 98
07:46 ET	Schering-Plough Reports Sales, Earnings for First Quarter of 1998
Apr 13, 98
08:24 ET	Schering-Plough Submits PLA for INTRON(R) A Treatment of Chronic Myelogenous Leukemia
Apr 06, 98
18:21 ET	Schering-Plough and Centocor Announce International Licensing Agreement For AVAKINE(TM) Monoclonal Antibody
Mar 19, 98
08:08 ET	Schering-Plough and Chugai Pharmaceutical In Agreement on Marketing Rights For New Treatment of Psoriasis
Mar 16, 98
08:28 ET	Schering-Plough and Ribi ImmunoChem Announce Distribution Agreement For MELACINE(R) Melanoma Vaccine
Feb 04, 98
08:26 ET	Schering-Plough and Transgene Collaborate on Gene Therapy Delivery Technology
Jan 28, 98
08:30 ET	Schering-Plough and Novo Nordisk Announce Copromotion Agreement For PRANDIN(TM) and Diabetes Care Products
Jan 27, 98
10:54 ET	Schering-Plough Declares Regular Quarterly Dividend
06:57 ET	Schering-Plough Reports Sales, Earnings For 1997 Full Year and Fourth Quarter
Jan 20, 98
08:23 ET	Schering-Plough Reports Status of NDA for INTRON(R) A Plus REBETOL(R) Combination Therapy for Chronic Hepatitis C
Jan 14, 98
08:49 ET	Oncormed to Provide p53 Pharmacogenomic Services for Schering-Plough Clinical Trials
Jan 12, 98
08:10 ET	Schering-Plough Submits Centralized Marketing Authorization Application in EU For TEMODAL(R) as Treatment for Brain Tumors
Jan 05, 98
10:40 ET	Schering-Plough Licenses PROMETRIUM(R) Marketing Rights To Solvay Pharmaceuticals
08:09 ET	Schering-Plough and Genzyme Molecular Oncology Collaborate on Gene Therapy Delivery Technology
Dec 23, 97
13:25 ET	W. H. Conzen, Former Schering-Plough Chairman of the Board, Dies at Age 84
Dec 18, 97
08:43 ET	Schering-Plough Completes $500 Million Share Repurchase Program, To Commence New $1 Billion Share Buyback
Dec 09, 97
08:07 ET	Schering-Plough Submits NDA For INTRON(R) A Plus REBETOL(TM) Combination Therapy for Chronic Hepatitis C
Dec 08, 97
11:50 ET	Schering-Plough Appoints Chang Vice President, Chief Scientific Officer, of Canji Gene Therapy Unit
08:34 ET	Schering-Plough and Sepracor In Licensing Agreement On CLARITIN(R) Metabolite
Dec 03, 97
08:08 ET	Schering-Plough Announces Availability of FARESTON(R) as First-Line Treatment of Metastatic Breast Cancer
Nov 20, 97
12:47 ET	Schering-Plough Reports on Clinical Progress of P53 Gene Therapy at Annual Gene Therapy of Cancer Meeting
Nov 17, 97
08:19 ET	Schering-Plough in Agreement with Zonagen For Worldwide Marketing Rights to VASOMAX(TM) for Treatment of Male Erectile Dysfunction
Nov 10, 97
08:16 ET	Schering-Plough Announces FDA Clearance of INTRON(R) A for Non-Hodgkin's Lymphoma
Oct 28, 97
11:13 ET	Schering-Plough Declares Regular Quarterly Dividend
Oct 21, 97
07:23 ET	Schering-Plough Reports Sales, Earnings For 1997 Third Quarter, First Nine Months
Oct 07, 97
12:03 ET	Schering-Plough Reports Third Quarter 1997 EPS, Announces $1 Billion Share Buyback Program, Reviews Research and Development Progress
07:57 ET	Schering-Plough Announces NASONEX(R) Receives Positive Conclusion To EU Recognition Procedure For the Treatment of Allergy Symptoms
Oct 03, 97
08:34 ET	Schering-Plough Announces U.S. Marketing Clearance for NASONEX(R) Nasal Spray for Allergies
Sep 24, 97
08:15 ET	Schering-Plough and Genome Therapeutics Announce Alliance to Develop Antifungal Pharmaceutical Products
Sep 22, 97
08:50 ET	Schering-Plough Announces Phase III Results for INTRON(R) A Plus Ribavirin in Treating Hepatitis C
Sep 04, 97
08:34 ET	Schering-Plough Submits BLA for INTRON(R) A Pediatric Use in Chronic Hepatitis B
Sep 03, 97
08:22 ET	Schering-Plough and Reckitt & Colman in Agreement on Worldwide Marketing Rights for Buprenorphine Products
Jul 22, 97
06:59 ET	Schering-Plough Reports Sales, Earnings For 1997 Second Quarter, First Half
Jul 01, 97
08:45 ET	Schering-Plough Completes Acquisition of Mallinckrodt Animal Health Business
Jun 27, 97
02:34 ET	Schering-Plough and Chiroscience To Develop New Oral Treatments For Asthma, Inflammatory Diseases
Jun 26, 97
08:34 ET	Donald L. Miller Elected to Schering-Plough Board of Directors
Jun 24, 97
14:17 ET	Schering-Plough Approves Revised Shareholder Rights Plan
11:08 ET	Schering-Plough Declares Regular Quarterly Dividend
Jun 12, 97
08:06 ET	Schering-Plough and Corvas Announce Collaboration On Hepatitis Research
Jun 02, 97
11:03 ET	Schering-Plough Announces FDA Clearance of FARESTON(R) as First-Line Treatment of Metastatic Breast Cancer
08:27 ET	Schering-Plough Researchers Identify Promising Drug Target in Hepatitis C Virus
May 21, 97
07:45 ET	Schering-Plough Reviews Research and Business Progress, Sharpens 1997 Earnings Projection
May 19, 97
08:10 ET	Schering-Plough to Acquire Mallinckrodt Animal Health Business
Apr 23, 97
08:13 ET	Schering-Plough and Myriad Genetics Announce Strategic Collaboration
Apr 22, 97
15:08 ET	Schering-Plough Annual Meeting Highlights Worldwide Performance, Commitment to Pharmaceutical Research
12:18 ET	Schering-Plough Board of Directors Declares 2-for-1 Stock Split, Dividend Increase
Apr 17, 97
07:11 ET	Schering-Plough Reports Sales, Earnings For First Quarter of 1997
Apr 14, 97
08:26 ET	Schering-Plough Announces NASONEX(TM) Allergy Nasal Spray Receives Marketing Authorization in U.K., France
Apr 11, 97
10:35 ET	Schering-Plough: New Asthma Inhaler Now Available That Provides Consistent Dosing of Medication Without Releasing Ozone-Damaging CFCs
Mar 26, 97
14:49 ET	FDA Extends Hepatitis C Dosing Regimen for Schering-Plough's INTRON A; Physicians Can Now Tailor Therapy for Chronic Hepatitis C Patients
Mar 18, 97
08:39 ET	Schering-Plough Sells Rights to Interleukin-11 to American Home Products Corporation
Feb 28, 97
17:14 ET	President of Mexico Keynote Speaker As Schering-Plough Mexico Dedicates Pharmaceutical Manufacturing Facility
Feb 27, 97
08:20 ET	Schering-Plough Sees Strong Performance in 1997, Raises R&D Spending Projection
Feb 18, 97
08:33 ET	Schering-Plough Submits New Drug Application For Treatment of Psoriasis
Jan 28, 97
11:59 ET	Schering-Plough Declares Regular Quarterly Dividend
Jan 27, 97
09:31 ET	Schering Canada and University of Toronto Announce Research Collaboration to Develop Treatments for Alzheimer's Disease
09:29 ET	/C O R R E C T I O N -- Schering Canada/
08:39 ET	Schering Canada and University of Toronto Announce Research Collaboration to Develop Treatments for Alzheimer's Disease
Jan 23, 97
08:39 ET	Schering-Plough Reports Sales, Earnings For 1996 Full Year and Fourth Quarter
Jan 15, 97
08:23 ET	European Union CPMP Authorizes Unified Labeling for INTRON A in Member States
Jan 02, 97
08:45 ET	Schering-Plough Announces U.S. Marketing Clearance For VANCERIL 84 mcg Double Strength
Dec 23, 96
16:56 ET	Schering-Plough and Genome Therapeutics Announce Genomic Collaboration for Novel Asthma Therapeutics
11:54 ET	Schering-Plough Receives U.S. Marketing Clearance For New CLARITIN RediTabs; First Prescription Drug Available in U.S. in a Rapidly Disintegrating Tablet
08:51 ET	Schering-Plough and Genome Therapeutics Announce Genomic Collaboration for Novel Asthma Therapeutics
Dec 17, 96
09:26 ET	Schering-Plough Board Elects Bryce, President of HealthCare Products, A Corporate Executive Vice President
Dec 04, 96
08:14 ET	Schering-Plough Files Patent Infringement Suit Against Amgen on INFERGEN
Oct 22, 96
11:38 ET	Schering-Plough Declares Regular Quarterly Dividend
Oct 16, 96
07:36 ET	Schering-Plough Reports Sales, Earnings For 1996 Third Quarter, First Nine Months
Oct 14, 96
08:47 ET	Schering-Plough Announces U.S. Marketing Clearance for CLARITIN Syrup, First Nondrowsy Antihistamine for Children
Oct 03, 96
12:57 ET	Schering-Plough Addresses Analyst Group On Pharmaceutical Business, Research Progress
Oct 02, 96
08:18 ET	Schering-Plough Submits NDA For NASONEX Allergy Nasal Spray
Sep 25, 96
08:07 ET	Schering-Plough Announces $500 Million Share Buyback
Sep 24, 96
09:24 ET	After A Decade Of Research, First-Ever Medical Treatment For High-Risk Malignant Melanoma Is Making A Difference
Aug 26, 96
08:02 ET	Schering-Plough Receives U.S. Marketing Clearance For CLARITIN(R)-D 24 Hour Antihistamine/Decongestant
Aug 16, 96
12:22 ET	Schering-Plough in Agreement to Market 3M Pharmaceuticals' CFC-free Albuterol Inhaler
Jul 23, 96
08:11 ET	SCHERING-PLOUGH REPORTS SALES, EARNINGS FOR 1996 SECOND QUARTER, FIRST HALF